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Abstract 
The correlation between the chemical stability and the microbiological activity of 
polymyxin B in phosphate buffer pH 6.0 and in proprietary eye drops was evaluated. 
High Performance Liquid Chromatography (HPLC) was used to quantify the amount 
of the main components in samples stored at 43,50,55 and 60°C for a period of 500 
h. The data indicated that there are significant differences in chemical stability 
among the different proprietary eye drops. The accurate decomposition rate 
constants and shelf-lives (~o) at 4°C of two of the six formulated eye drops and the 
standard polymyxin B solution stored in glass containers at pH 6.0 were established. 
It was concluded that microbiological assay by agar diffusion was unsuitable for 
determining the activity of control polymyxin B in phosphate buffer and polymyxin 
B in eye drops. Killing time determinations for polymyxin B against cell 
suspensions of P. aeruginosa NCTC 6750 were consequently used. Thioglycollate 
broth containingp- aminobenzoic acid (PABA) 0.16 %w/v and magnesium sulphate 
1 %w/v was used as an inactivating recovery medium. The effect of preservatives 
and of second antibacterials contained in the eye drops were tested individually and 
combined with polymyxin B. Thiomersal 0.001 %w/v, trimethoprim 0.02 %w/v 
and thiomersal 0.001 %w/v plus trimethoprim 0.02 %w/v did not have an effect on 
the activity of polymyxin B 2000 U/ml. Neomycin was an exception and at the 
concentrations in the range 0.0192 to 0.16 %w/v exhibited an antagonistic effect. 
Chemical interaction between polymyxin B and neomycin could not be detected and 
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it was considered that the inhibitory effect of neomycin may be the result of 
competition between polymyxin B and neomycin for the same binding sites on the 
cell surface. 
Gentamicin is active against P. aeruginosa NCTC 6750 and at concentrations of 
0.075 and 0.036 %w/v it exhibited an additive effect with polymyxin B 2000 U/ml 
against the test organism. 
The results obtained with the samples stored at 55°C for a period of 500 h 
demonstrated the critical effect of pH. At a pH of 6.0 microbiological activity and 
chemical stability appeared optimal. The chemical stability data of five eye drop 
samples correlated with microbiological activity data. Exceptions were polymyxin 
B in one eye drop sample and control polymyxin B. These extensively decomposed 
samples showed good antibacterial activity which appeared to result from the 
activity of decomposition products. Chemical stability data for standard polymyxin 
B solution at pH 6.0 also correlated to microbiological activity data over the 
temperature range of 92 - 115°C. The polymyxin B retained detectable 
microbiological activity when the amount of PB 1 was greater than 20%. It is 
suggested that the decomposition products which occurred at these higher 
temperatures did not possess antibacterial activity . 
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Chapter 1 Introduction 
1.1 A review of the polymyxins 
1.1.1 History 
The polymyxins are a group of closely related decapeptide antibiotics produced by 
species of Bacillus and with selective action against Gram-negative bacilli. They 
were isolated independently in 1947 in a laboratory in Britain and two laboratories 
in the United States. The British investigators called the antibiotic 'aerosporin' 
since they identified the bacillus as Bacillus aerosporus. The American 
investigators identified the bacillus as Bacillus polymyxa and called the antibiotic 
polymyxin. Comparative studies in the two laboratories proved that the 'two 
bacilli' was the same organism and the name polymyxin was agreed [1]. 
1.1.2 Structure 
The polymyxin group comprises of polymyxins, colistins and circulins which have 
similar chemical structure. For polymyxins, eleven components have been 
distinguished (A, B, C, D, E, F, K, M, P, S, T) and these can be separated further 
into (for example) BI and B2 [2]. Polymyxin A is the antibiotic originally named 
aerosporin and polymyxin D is the polymyxin isolated by Stansly et al in 194 7 [via 
1]. Only two of polymyxins have found clinical usefulness, namely polymyxin B, 
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usually in the form of sulphate, and polymyxin E (colistin), either as the sulphate or 
sodium sulphomethate. The major constituents of commercial polymyxin Bare 
polymyxin BI , B2 and B3 [3]. 
The polymyxins have a general structure composed of a cyclic heptapeptide moiety 
and a side chain consisting of a tripeptide acylated at the N-terminus. They differ 
from each other in amino acid composition and each polymyxin consists of a 
mixture of polypeptides with an identical amino acid composition but with a 
different terminating fatty acid as shown in Fig.I.1 and 1.2 [4,5]. Thus, each 
polymyxin may be subdivided corresponding to at least three fatty acid components: 
6-methyloctanoic acid, 6-methylheptanoic acid or isooctanoic acid and n-octanoic 
acid. The characteristic feature of polymyxins, in addition to the hydrophobic fatty 
acid moiety, is their strong basicity due to four or five unmasked amino acid groups 
from 2,4-diaminobutyric acid [6]. 
For polymyxin B, important things to note are the cyclic portion (7a) made up of 
seven amino acid residues and the acyl tripeptide tail. Of the ten amino acid 
residues present, all except phenylalanine are of the L-configuration. Of the six 
diaminobutyric acid residues, five provide a free side chain amino group and the 
sixth holds together the cyclic moiety and acyl tripeptide segment. Two hydrophilic 
side chains are provided by the threonine residues. At ordinary pH the antibiotic 
will be a polycation. The acyl group and amino acid groups of residues 1 and 3 of 
polymyxin B need to be intact for biological activity. Neutral amino acid 
substitution at locations corresponding to residues 8, 9 and 10 in the cyclic portion 
2 
of such molecules seems permissible. The residue at location 6 needs to be of the 
D-configuration. If the L-diaminobutyric acid at position three is replaced either by 
the D-diaminobutyric acid or a neutral D-amino acid, then residues 1 and 2 of 
polymyxin B become dispensable. A C7-9 acyl group would still seems to be 
essential [7]. 
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Fig.1.2 Structure of polymyxin 8. 
1.1.3 Chemical properties 
The polymyxins (molecular weight 1000-2000) were shown to be stable in the pH 
range 2.0-7.0 even when heated but unfortunately the time and temperature of 
heating were not stated [8]. Under more acid or alkaline conditions the polymyxins 
lost their activity after 36 hours at room temperature [8]. The same workers showed 
that pepsin, trypsin, erepsin and pancreatin were not found to inactivate the 
polymyxins, but lipase decomposes polymyxin B and a polymyxin related 
compound known as circulin. They also showed that polymyxins were adsorbed 
onto paper and Seitz filters. 
Polymyxin B sulphate is a white or buff-coloured, hygroscorpic powder, odourless 
or with a slight odour. The B.P. specifies that it contains not less than 6500 units 
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per mg and the U.S.P. specifies not less than 6000 units of polymyxin B per mg. 
Both specifications are for the dried substance. One unit of polymyxin B is 
contained in 0.000119 mg of the second International Standard Preparation (1969) of 
polymyxin B sulphate which contains 8403 units per mg. The commercially 
available forms of polymyxin B sulphate are generally less pure than the 
International Standard Preparation and doses are sometimes stated in term of pure 
polyn1yxin base: 100 mg of pure polymyxin B is considered to be equivalent to 1 
million units (lmega unit )[9,10]. Polymyxin B sulphate is highly soluble in water 
and methanol ~ solutions are fairly stable and is stated to withstand heating to 60°C 
for one hour [1]. Its aqueous solutions are slightly acidic or nearly neutral. The 
B.P. states that a 2% solution in water has a pH of 5 to 7, and the U.S.P. states that a 
0.5% solution has a pH 5.0 to 7.5, and when refrigerated, is stable for at least 6 
months. Alkaline solutions are not stable. Moisture content should not be more 
than 6%, determined by drying over phosphorous pentoxide at 60°C under vacuum. 
The dissociation constant (pKa) is 8.9[9,10]. 
1.1.4 Mechanism and site of action 
The polymyxins are bactericidal for a broad range of Gram-negative bacteria but 
they have less effect on Gram-positive bacteria. They cause leakage of small 
molecules, such as phosphates and nucleosides from sensitive bacteria. The extent 
of the leakage is proportional to the killing effect of the drug. Alterations in 
membrane permeability is one of the earliest changes caused by the polymyxins, and 
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their effect on the outer cellular functions, such as respiration and A TP levels, are 
thought to be entirely secondary to membrane damage. 
It is likely that the polymyxins are not very active against Gram-positive bacteria 
because the thick cell wall prevents access to the cytoplasmic membrane. In 
causing a change in the cytoplasmic membrane permeability of Gram-negative 
bacteria. the polymyxins must either first disrupt the permeability of the outer 
membrane or pass through the outer membrane and interact with the cytoplasmic 
membrane [11]. Kubesh and Beggs [12] proposed that polymyxin B crosses the 
outer membrane and subsequently disrupts the cytoplasmic membrane, possibly by 
causIng interdigitation of some domains of gel phase lipid containing saturated 
chains. At low concentrations, polymyxin B causes changes in the morphology of 
the outer membrane and causes selective release of proteins that are located in the 
periplasmic space between the inner and outer membranes. The drug can also alter 
respiration either directly by interacting with the cytoplasmic membrane, which is 
the site of electron transport and oxidative phosphorylation, or indirectly by 
perturbation of the outer membrane structure. 
Polymyxins are cyclic polycationic peptides with a fatty acid chain attached to the 
peptide through amide linkage. The heptapeptide polar head and nonpolar fatty acid 
chain confer amphipathic properties which permit the polymyxins to interact with 
both lipopolysaccharides and phospholipids [13]. The heptapeptide head binds to a 
high-affinity binding site on lipopolysaccharide that is also a binding site for 
calcium and magnesium ions, which are known to play important roles in stabilising 
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the structure of membranes particularly the outer membrane of Gram-negative 
bacteria. It is proposed that polymyxins may act by competitively displacing 
calcium and magnesium ions from negatively charged phosphate groups on 
membrane lipids. This would be the effect of the charged cycloheptapeptide while 
the insertion of the fatty acid side chain into the core of the membrane would perturb 
the normal packing of the phospholipids. The two interactions together could 
disrupt the membrane organisation to an extent that would increase permeability to 
polar or charged molecules [14,15]. The effects of the polymyxins are shown in 
Fig. 1.3 [16]. 
PB 1 and PB2 differ only in the fatty acid residue terminating the tripeptide chain. 
PB 1 terminates in a methyloctanoic acid residue and PB2 terminates in a 
methylheptanoic acid residue. Thus, PB 1 and PB2 have a similar antibiotic 
mechanism and may be expected to have a similar quantitative antibiotic effect [15]. 
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l.l.5 Antimicrobial activity and resistance 
The antimicrobial activity of five members ( A to E ) of the polymyxin group is of a 
similar nature. However, they are all nephrotoxic although this effect is much 
reduced with polymyxin B and polymyxin E (colistin). The spectrum of clinical 
action of the polymyxins is limited to Gram-negative bacilli. Gram-positive 
bacteria and obligate anaerobic bacteria are resistant. Escherichia coli, Klebsiella 
pneumoniae, and the following species Enterobacter, Salmonella, Shigella, 
Haemophilus, Pasturella and Bordetella are usually susceptible. Classical Vibrio 
cholerae is sensitive. Proteus, Providencia, Serratia and Neisseria species are 
usually resistant. Some fungi such as Coccidiodes immitis are susceptible but most 
are resistant [9,11]. Minimum inhibitory concentrations of polymyxin B sulphate 
for the most sensitive species generally range from about 0.01 to 4 ~g per ml [9]. 
Polymyxins have been reported to demonstrate antimicrobial synergy with a variety 
of other agents, including chloramphenical, tetracyclines, sulphonamides and 
trimethoprim. Polymyxins have been shown to be synergistic with trimethoprim 
and sulphamethoxazole against several multiply drug-resistant, Gram-negative 
bacilli (e.g. Serratia marcescens, Pseudomonas cepacia and Pseudomonas 
maltophilia). Synergism has also been demonstrate with rifampicin against 
multiresistant Serratia species. The mechanism of the synergism is probably the 
same as that observed with polymyxin B and tetracyclines against fungi at 
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concentrations where each drug alone has no effect. The polymyxin B increases the 
permeability of the yeast cell membrane to tetracyclines, which then inhibits protein 
synthesis and causes cell death [9,11]. Richards and Xing found [1 7] that 
subinhibitory concentrations of combinations of any two of ciprofloxacin, colistin 
(or polymyxin B), sodium sulphadiazine and p-aminobenzoic acid had synergistic 
inhibitory activity against P. aeruginosa and had synergistic or additive activity 
against Staphylococcus aureus. In addition sulphadiazine plus either ciprofloxacin 
or polymyxin showed markedly enhanced killing activity against both P. aeruginosa 
and S. aureus. p-Aminobenzoic acid plus either ciprofloxacin or polymyxin also 
demonstrated enhanced killing activity against P. aeruginosa but the combinations 
were less effective in enhancing activity against S. aureus. Ciprofloxacin in 
combination with polymyxin had a marked synergistic effect against P. aeruginosa 
but only a slight effect against S. aureus. 
P. aeruginosa has been found to be resistant to polymyxin B in vitro [18-20]. It is 
suggested that polymyxin-susceptible cell populations adapt to polymyxin by the 
rapid alteration of the cell envelopes of the entire cell population. Cell envelope 
phospholipases and protease may playa major role in an adaptive response and the 
cation content of the cell envelope may be a critical controlling factor in the process 
[19]. Bell and Hancock [21] proposed that overall expression of divalent cation-
regulated outer membrane protein HI of P. aeruginosa is associated with resistance 
to polymyxin B. Protein HI is believed to act by replacing divalent cations at 
binding sites on lipopolysaccharide, thereby preventing disruption of the sites and 
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subsequent self-promoted uptake of the antibiotic. In addition, loss of hydroxy fatty 
acid from lipopolysaccharide may perturb outer membrane hydrophobicity and is a 
contributing factor to polymyxin B adaptive resistance [20]. 
1.1.6 Clinical use 
The polymyxins are used parenterally almost exclusively to treat serIOUS 
P.aeruginosa or other Gram-negative bacillary infections caused by strains resistant 
to other drugs or in patients who cannot tolerate the preferred drugs. Because of 
their severe toxicity ( neurotoxicity, nephrotoxicity and neuromuscular 
blockade ),they are not the drug of first choice for the treatment of any specific 
infection[9, 11 ]. The advent of carbenicillin derivatives like ticarcillin, the 
ampicillin derivatives like ureidopenicillins and also piperacillin and extended 
spectrum cephalosporins means that severe Gram-negative infections including 
those caused by P. aeruginosa can now be treated with less toxic agents than the 
peptide antibiotics or even the aminoglycosides. The use of parenteral polymyxins 
has therefore declined. They can be used to treat bacteraemia or urinary tract 
infection but are not effective in the treatment of deep tissue infections or infections 
in granulocytopenic patients [3,11]. 
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Polymyxin B is the most commonly used polymyxin. It is used topically, often in 
combination with other antibiotics to extend the antimicrobial spectrum, in the 
treatment of eye, ear and skin infections due to susceptible organisms [9]. 
Polymyxin B has been combined with many other antibacterial agents including 
neomycin, bacitracin, oxytetracycline, trimethoprim, framycetin, gramicidin, 
chloramphenicol, kanamycin, nystatin and tyrothricin. Polymyxins have been 
formulated in various topical dosage forms such as ointments, creams, gels, 
solutions. aerosols, powders, eye and ear drops both in the form of solutions and 
suspensIons. F or example, eye drops of polymyxin B with neomycin and 
gramicidin have been used prophylactically to prevent infections in patients 
undergoing ocular surgery and conjunctival inflammatory disorders. More recently, 
trimethoprim with polymyxin B drops ( PolytrimR) have become available for 
superficial bacterial eye infections. They are intended for use in bacterial infection 
of the eye including blepharoconjunctivitis, conjunctivitis, keratitis and corneal 
ulceration, and for prophylaxis in eye surgery and trauma. Polymyxin B 
complements the action of trimethoprim which is active against most common 
Gram-positive and Gram-negative organism except P. aeruginosa. The 
combination provides useful broad-spectrum antibiotic activity. A combination of 
both drugs produced identical clinical and microbiological responses when 
compared with a solution containing trimethoprim , polymyxin Band 
sulphacetamide. The sulphadiazine component was not thought to be essential to 
produce the desired clinical and microbiological results. The antibacterial spectrum 
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of trimethoprim and polymyxin B eye drops resembles that of polymyxin B and 
bacitracin eye ointment (PolyfaxR) and polymyxin B, gramicidin and bacitracin eye 
drops (NeosporinR). It has no advantage over them except as an alternative in a 
patient hypersensitive to one of the other constituents. Its activity against P. 
aeruginosa gives it a slight advantage over chloramphenicol. The preservative in 
polymyxin eye drops (thiomersal) can cause keratoconjunctivitis, particularly in soft 
contact lens wearers. This disadvantage and the expense means that the cheaper 
chloramphenicol eye drops remain the eye drops of choice in the routine 
management of bacterial infections [22-25]. 
Trimethoprim and polymyxin B are also combined in ophthalmic ointment. There 
was no statistically significant difference between trimethoprim-polymyxin B 
ophthalmic ointment and chloramphenicol ophthalmic ointment with regard to 
eradication of organisms or clinical improvement in the treatment of bacterial 
conjunctivitis and the prophylaxis of infection in patients undergoing cataract 
surgery [26-27]. A combination of hydrocortisone acetate-polymyxin B showed no 
significant difference in therapeutic efficacy from a combination of hydrocortisone 
butyrate-oxytetracycline in the local treatment of acute external otitis except for 
S. aureus which was cultured from 17% of the patients [28]. 
Polymyxin B-trimethoprim cream has been used in the treatment of superficial 
infection of the skin and pyoderma. A combination of 0.17% mg/g trimethoprim 
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and 10,000 IU/g polymyxin B was more effective than a 20 mg/g fusidic acid cream 
in reducing the signs of crust and tenderness , alleviation severity of pyogenic 
infection of the skin and reducing the overall severity score at the end of the two 
\veeks study in 87 patients [29]. Polymyxin B is also combined with neomycin and 
bacitracin in an ointment used in the treatment of skin infections [30,31]. Other 
dosage forms such as sprays and aerosols are effective in the treatment of wound 
infections [32.33]. 
1.1.6 Analytical methods for polymyxin B 
Various analytical methods such as countercurrent distribution, spectrophotometric 
or fluorimetric methods, column chromatography, thin layer chromatography (TLC), 
gas chromatography, high performance liquid chromatography (HPLC) and 
electrophoresis have been used to separate various components of polymyxins 
[34,35]. 
Spectrophotometric and fluorometric methods 
Several spectrophotometric and fluorometric methods have been developed for 
polymyxin B. Both methods involve treatment of polymyxin with some reagents to 
make a colour complex or fluorescence derivatives that can be detected at a specific 
wavelength. Many reagents such as bromthymol blue, sodium hypobromite, 
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a-aminocarboxylic acid with sodium hypobromite, ninhydrin and fluorescamine 
have been used [36-40]. The disadvantages of these methods are non-specificity 
and the incapability of differentiating various components of polymyxin B [37]. 
However, they are useful for the quantification of polymyxin B components after 
separation by other methods e.g. TLC and electrophoresis. 
Column chromatography 
Haemers and Moerloose [41] reported a column chromatography determination of 
polymyxin B sulphate . Polymyxin B was taken up by a weakly acid 
polysaccharide ion-exchange resin with carboxyl groups in citrate buffer, pH 6.2, 
and eluted by a continuous ionic strength gradient at the same pH. The antibiotic 
was determined in the eluate with ninhydrin by means of an Auto-Analyzer. This 
was applied to polymyxin B bulk samples, tablets, hydrophilic ointments and aerosol 
powders. Good correlation between chemical and biological results in preparations 
where polymyxin B was partially degraded was obtained. This method can be 
considered as a specific and stability-indicating assay for polymyxin B sulphate and 
it was accepted as a valuable substitute for the microbiological method. The 
procedure offered greater accuracy and reproducibility (standard deviation 2.8%) 
than the microbiological method. However, the complication of the method and 
the long retention time (2.4 h) makes it not suitable for routine use. In addition this 
method cannot provide the information on separation and quantification of 
individual components of polymyxin B. 
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Thin-layer chromatography (TLC) 
TLC is the method recommended in The British Pharmacopoeia for the 
identification of polymyxin B [42]. Different media and mobile phases have been 
used by several workers in order to separate its individual components [35]. 
Thomas et al [43] used pre-coated silica gel plates and the mobile phase consisted of 
acetonitrile-hydrochloric acid. Prior to chromatography, the plates were placed in a 
filter-paper lined chromatographic tank that had dried at 110°C for 30 minutes. 
The samples were applied to the plates and developed. The plates were then 
removed from the tank and the separated components detected with ninhydrin 
reagents. The ninhydrin-treated chromatoplates were scanned at 570 run, using the 
thin-layer chromatography accessory of a fluorescence spectrophotometer. Thomas, 
A.H. and Thomas, J.M. [44] applied the use of the Optomax ( a modular image 
analysis system ) for the measurement of zones of inhibition of growth and 
ninhydrin zones. The relative proportions of PB 1 and PB2 were determined in 
samples of polymyxin after TLC separation on the basis of antimicrobial activity and 
ninhydrin reactivity. The incomplete separation of polymyxin and the lack of 
sensitivity for the minor components meant that only the two major components 
could be quantified. 
Gas-liquid chromatography (GLC) 
GLC has been used to measure the fatty acids present in polymyxin B in order to 
discover the relative composition of the material and it is included in the monograph 
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for colistin in the British Pharmacopoeia [45]. The details of fatty acids assay were 
as follo\vs. Polymyxin was hydrolysed with hydrochloric acid, the hydrolysate was 
extracted with ethyl ether and the fatty acids were separated with GLC on a column 
consisting of 200/0 diethylene glycol and 3% phosphoric acid on chromo sorb G 
[ 42.45.46]. 
High-perfom1ance liquid Chromatography (HPLC) 
Analysis of the polymyxin by high-performance liquid Chromatography was 
developed in recent years. There are quite a few publications in the literature, but 
different HPLC systems were used according to different conditions. In general, the 
columns were packed with Spherisorb ODS 5 f.lm diameter particles. The samples 
were dissolved in the mobile phase and were injected on to the column. The 
detector was operated from 185 to 220 nm and the peak areas were measured with an 
electronic integrator. The results are given as the percentage of the total area 
produced by each component [3,5,6,34,44,47-56]. 
The compendial methods of quantitative analysis for polymyxin B in the British , 
European and United States Pharmacopoeias are currently microbiological. These 
microbiological methods are capable of great sensitivity but their disadvantage is the 
lack of reproducibility of the potency determinations between laboratories, 
especially where the dose-response lines of the standard and test are not parallel. If 
suitable chemical methods are available they are usually more reliable, reproducible 
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and preCIse [5]. Both gel electrophoresis and TLC have proved invaluable in 
demonstrating the heterogeneous nature of many antibiotics [44]. The assay of 
fatty acid by gas-liquid chromatography is a reproducible and reliable method for 
determining the relative proportions of the main polymyxin components present in a 
sample. However, because of the hydrolysis and extraction procedures, it would be 
difficult to adapt this method to the quantitative determination of the polymyxin on a 
mass basis. High performance liquid chromatography provides the most 
information on the composition of the polymyxin sample and it would be the method 
best suited to monitoring the composition of polymyxin in order to ensure that 
material of a known composition is used. However, because of the complex nature 
of the polymyxin, it is difficult to suggest a suitable chemical assay to replace the 
microbiological assay. In the case of antibiotics, a chemical method is valueless if 
the results differ from those obtained by the microbiological method [43]. It is 
suggested that in the first instance, a comparison of the HPLC assay with the 
microbiological assay should be carried out [34]. 
Only two publications reported chemical stability studies of polymyxin B. Taylor 
et al [55] used HPLC assay to carry out a stability study and showed that polymyxin 
B alone in aqueous solution was not stable for long periods of time (shelf-life (t90) 
= 130 days at 40C). Dreyer-van der Glas et al [56] developed a stability indicating 
method of analysis for polymyxin B in eye and ear drops and they demonstrated a 
shelf-life (t90) of at least 18 months at 40C. These two investigations yielded 
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different shelf-lives of polymyxin B and only a chemical assay was used to 
determine the rate constants. 
Both a microbiological assay and a chemical assay were used in three publications. 
Good correlation between both methods were obtained by comparison of column 
chromatography data with microbiological data both in terms of total polymyxin B 
[41] and TLC data with microbiological data in terms of PB 1 and PB2 [44]. 
However. the information of individual components of polymyxin B was not clearly 
demonstrated. Thomas et al [42] used a microbiological assay, TLC,GLC, and 
HPLC to examine the potency and composition of polymyxin B and polymyxin E 
from different sources. It was found that there was no correlation between the total 
proportion of the two major components in each polymyxin determined by either 
GLC or HPLC and the microbiological potency. Although a microbiological assay 
and chemical assay were used in this study, the stability of polymyxins was not 
investigated. There are no reports in the literature concerning the relationship 
between chemical stability and microbiological activity of polymyxin preparations. 
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1.2 Purposes of this work 
The purpose of the present work was to develop HPLC and microbiological methods 
capable of determining the chemical stability and microbiological activity of 
polymyxin B in solutions. It was intended to develop both methods for standard 
material and various eye drop formulations also containing other added ingredients 
(trimethoprim. neomycin. gramicidin, metaoxedrine, thiomersal and benzalkonium 
chloride). It was also intended to use both methods to monitor the concentration of 
polymyxin B components and their microbiological activity during a decomposition 
process. This would allow correlation of microbiological activity data with 
chemical stability data which has not been found in the literature. Such correlation 
would add significantly to existing knowledge of the overall action of the drug and 
would possibly provide new insights into its stability in formulations. 
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Chapter 2 HPLC assay development 
2.1 Introduction 
Analysis of polymyxin B by high performance liquid chromatography(HPLC) has 
been developed using several different systems. Polymyxin B components were 
first separated by using gradient elution [47]. An isocratic HPLC method is 
preferred over a gradient one due to the fact that laboratory automation can be more 
easily and inexpensively accomplished with an isocratic system [48]. The first 
isocratic HPLC method for the analysis of PB1 and PB2 was reported by Fong and 
Kho [48]. The method uses a 25 cm Hypersil-ODS (5 /-lm) column, a mobile phase 
containing 22.5 % acetonitrile in an aqueous phase with tetramethylammonium 
chloride (TMAC), a flow rate of 1.0 ml/minute and a wavelength of 220 nm 
detection. Complete resolution of PB 1 and PB2 and their separation from all other 
components and/or impurities was achieved in less than 23 minutes. The effect of 
mobile phase components on the separation of polymyxin B, the linearity and the 
lower limit of detection were investigated. Terabe et al [48] successfully separated 
seventeen_components of the polymyxins ( MJ, M2, DJ, D2, CJ, C2, SJ, EJ, E2, BJ, B2, 
B3, FJ, F2, F3,TJ, T2 ) using Nucleosil 5C18 column with tartrate buffer-acetonitrile 
containing sodium 1-butanesulphonate and sodium sulphate as the mobile phase. 
Kimura et al [50] used different system to separate polymyxin A, B, D, E, K, M and 
P. A porous styrene-divinylbenzene copolymer column and methanol : 0.2 M 
potassium chloridelhydrochloric acid buffer (PH 2.0) (1: 1) as a mobile phase were 
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employed. Thomas et al [43] used a Spherisorb C18 column and a mobile phase 
consisting of tartrate buffer (0.005 M), pH 3.0, sodium butane I-sulphonate (0.05 
M), sodium sulphate (0.2 M) and acetonitrile (18%v/v). The different proportions of 
polymyxin B components from different sources was shown. Fisher and Raja [5] 
suggested that the mobile phase used by Terabe et al and Thomas et al causes many 
problem owing to crystallisation of solutes in pump heads, valves and injectors 
\yhich is unsatisfactory and occasionally expensive. They used a column packed 
\\ith 5 /-lm Hypersil C18 and water-methanol-methanesulphonic acid (250+250+5) 
as the eluent and claimed that there was no potential problem of crystallisation of 
buffer from the mobile phase, making it ideal for routine use. Similar to Thomas et 
al. the polymyxin B was divided into three groups according to the difference in 
proportion of PBl and PB2. Whall [51] reported the complete separation of the 
three major components using Altex-Ultrasphere ion-pair column and a mobile 
phase containing acetonitrile-phosphate buffer. This system was simple and rapid. 
Linearity and limit of detection were also reported. At approximately the same time, 
Elverdam [52] developed the system to separate polymyxin B into ten to thirteen 
components using a chemically bonded C 18 stationary phase and a mobile phase 
consisting of a mixture of acetonitrile/formate and acetate buffer. Recently, 
separation of polymyxins by micellar electrokinetic capillary chromatography has 
been reported [6]. The method developed is useful for both qualitative and 
quantitative measurements on polymyxins. The variations between the relative peak 
areas of the main peaks from difference sources was described. 
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As mentioned by Taylor et al [55], most of the information appeanng In the 
literature is concerned with separation. There are only three papers which describe 
the quantitative analysis of polymyxin B. Whall [51] reported the linearity and 
detection limit of polymyxin B. Fong and Kho [48] also described the linearity and 
detection limit of polymyxin B, but only two components are resolved and the 
quantitation is in terms of the sum of these peaks. The publication by Fisher and 
Raja [5] estimates the relative proportions of each of the major components by peak 
normalisation. 
Two recent publications have described HPLC as stability indicating methods of 
analysis of polymyxin B. Dreyer-van der Glas et al [56] used a 60-RP-select B 
column and a mobile phase containing 0.01 M diethylamine (adjusted to pH 2.5 with 
phosphoric acid and 0.064 M Na2S04) : acetonitrile, 78 : 22 v/v to assay polymyxin 
B eye and ear drops during a stability study. The influences of pH and ionic 
composition of the solution on the quantitative determination method of polymyxin 
B was not clearly described. Taylor et al [55] used two systems consisting of 3 J.lm 
ODS Hypersil and two mobile phases called solvent A and solvent B differing in 
composition of phosphate buffer, acetonitrile, perchloric acid and pH. Solvent A 
which containing 24:76 acetonitrile: aqueous 0.05 M disodium hydrogen phosphate 
adjusted to pH 2.9 was used to determined the percentage of polymyxin B remaining 
during an accelerated stability study. The quantitation of polymyxin B was based on 
the remaining peak height of PB 1 and PB2 which were in good agreement. The 
chromatographic variables affecting the separation, the validation of the assay and 
the specificity of the assay for polymyxin B in the presence of trimethoprim, 
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propamidine and dibromopropamidine were reported. However, the specificity of 
solvent A for the assay of polymyxin B in various eye drops formulations was not 
reported. It is suggested that solvent B may be suitable for use in the assay of 
polymyxin B in the presence of co-formulated antibacterial drugs since the inclusion 
of perchloric acid would improve the resolution and it is less critical than solvent A 
in routine use. The effect of chromatographic variables of solvent B on the 
separation was not studied. 
It was intended to investigate further the effect of chromatographic variables of 
solvent B on the separation of polymyxin B components. The results obtained from 
this investigation is necessary for mobile phase optimisation. It was also intended to 
report the quantitative aspects of assay validation for polymyxin B in the presence 
of the other ingredients by using the developed mobile phase. This would allow the 
appropriate chemical assay for polymyxin B to be used in the proposed stability 
study of the drug in various eye drop formulations. 
2.2 Materials and methods 
Chemicals and Reagents, apparatus and chromatographic conditions described below 
were employed in all experiments in Chapters 2 and 3. 
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2.2.1 Chemicals and Reagents 
Water used in the chromatography was purified by a Millipore Milli-Q system. 
HPLC grade acetonitrile(ACN) was obtained from Rathburn Chemicals. Polymyxin 
B sulphate (PMB), trimethroprim (TMP), neomycin sulphate (N), gramicidin (G), 
metaoxedrine or L-phenylephrine hydrochloride (M), benzalkonium chloride (BZK) 
and sodium hydroxide were purchased from Sigma. Thiomersal (TMS) was 
supplied by Aldrich Chemical. Disodium hydrogen phosphate (DSHP), perchloric 
acid, ammonia (SG 0.88, SLR grade), orthophosphoric acid, potassium dihydrogen 
orthophosphate (SLR grade) were supplied by Fisons. Polymyxin B eye drops were 
purchased from Wellcome (sample 1), Seng Thai (sample 2), Dispersa (sample 3) 
and Alcon (sample 4-6). (Table 2.7) 
2.2.2 Apparatus 
The HPLC system employed in this work comprised a Jasco PU 880 pump and UV 
2550 detector, a Rheodyne Model 7125 injector incorporating a 20 ~l loop and a 
BBC Goerz Servogor Type SE 210 chart recorder. The chromatographic column 
(100 X 4.6 mm) was slurry packed in the laboratory with 3 ~m ODS Hypersil. 
2.2.3 Chromatographic conditions 
The mobile phase was filtered through a 0.45 ~l Millipore filter Type HVLP prior to 
use. The column flow-rate was maintained at 1.5 mllmin. All measurements were 
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made at room temperature. The column was equilibrated with the mobile phase for 
about 30 minutes at the flow rate used for this work. The detector wavelength was 
set at 200 nm using the sensitivity from 0.08 to 1.28 AUFS, at a recorder input of 
10 mY. Recorder chart speeds between 0.2 and 0.5 cm/min were used. 
2.2.4 Separation development 
As the separation of polymyxin B in this work was based on a reverse phase 
separation, the magnitude of the separation depended on many factors, particularly 
the composition of the mobile phase which was, in this study, composed of 
acetonitrile as an organic modifier, pH , buffer and perchloric acid as an ion pairing 
agent. In the present work, each of these chromatographic variables was modified 
and the resultant effect on the separation of polymyxin B components was observed. 
The separation parameters ( capacity factor; k' and resolution; Rs) were calculated 
from the following equations [57]. 
(1) 
Where the retention time of solute is 1r and the retention time of solvent is to· 
Rs = tR2 - tRI / 0.5 ( WI + W2 ) (2) 
Where tR2 is the retention time of solute 2, tRI is the retention time of solute 1, WI is 
the peak width of solute 1 and W2 is the peak width of solute 2. 
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2.2.4.1 Effect of acetonitrile concentration 
The mobile phase was prepared by dissolving 3.58 g of DSHP and 3.85 g of 
perchloric acid (60 %w/v) in a mixture of water and acetonitrile to make the 
concentration of 0.01 M DSHP and 0.2702 % w/v perchloric acid. The volumes of 
acetonitrile and water were varied to obtain the concentrations of acetonitrile 
ranging from 25 to 50 % v/v. The pH was adjusted to 3.0 by addition of 
concentrated ammonia. 
The sample solution was prepared by weighting out accurately about 0.02 g of 
polymyxin B sulphate (8090 Vlmg) in a 10 ml volumetric flask and dissolving this 
in water to make a concentration of 16,250 Vim!' After the sample was injected at 
different concentration of acetonitrile, the retention time (tr)' separation and capacity 
factor (k') of the three components of polymyxin B (PB 1, PB2 and PB3) were 
recorded. 
2.2.4.2 Effect of pH 
A mobile phase consisting of 30:70 acetonitrile: aqueous 0.01 M DSHP and 0.2702 
% w/v perchloric acid was used in this experiment. The mobile phase was prepared 
by dissolving 3.58 g of DSHP and 3.85 g ofperchloric acid (60 % w/v) in a mixture 
of 300 ml acetonitrile and 700 ml water. The pH was adjusted by adding ammonia 
or orthophosphoric acid to obtain a range of pH from 2.0 to 5.5. 
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Samples containing 16,250 U/ml of polymyxin B were prepared by the method 
described in 2.2.4.1. After the sample was injected at different pH, the retention 
time (tr), and capacity factor (k') of the three components of polymyxin B (PB1, PB2 
and PB3) were recorded. The separation among the individual peaks was also 
qualitatively observed 
2.2.4.3 Effect of buffer concentration 
The solvent system consisted of 30:70 acetonitrile: aqueous DSHP and 0.2072 % 
wlv perchloric acid was used and prepared as described in 2.2.4.2. This solvent was 
recycled and the buffer concentration increased from 0.005 to 0.020 by addition of 
solid DSHP. 
Samples containing 16,250 U/ml, prepared as described in 2.2.4.1 were injected at 
each concentration of buffer after equilibration. The retention time (tr) and capacity 
factors (k') of the three components of polymyxin B (PB 1, PB2 and PB3) were 
recorded and the separation among the peaks observed qualitatively. 
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2.2"+"+ Effect of perchloric acid 
To confirm and extend the results of Taylor et al [54] concerning the effect of 
perchloric acid on the separation of polymyxin components, the effect of addition of 
perchloric acid was studied over an extended range of concentration. Since this 
resulted in considerable increases in retention, the concentration of acetonitrile was 
adjusted as appropriate to maintain the same overall separation time. 
The solvent system consisted of 28:72 acetonitrile: aqueous 0.01 M DSHP was 
prepared by dissolving 3.58 g of DSHP in a mixture of 280 ml acetonitrile and 720 
ml water. Perchloric acid was added to provide a range of concentrations from 
0.0348 to 0.6 %w/v. The pH was adjusted to 3.0 by addition of ammonia. 
Perchloric acid concentration was further increased from 0.6 to 5.0 %w/v by using 
mobile phase containing 40:60 acetonitrile: aqueous 0.01 M DSHP, pH 3.0 
adjusted by addition of ammonia. 
Samples containing 16,250 Vlml polymyxin B was prepared as the same method as 
2.2.4.1 and injected at each concentration of perchloric acid. The retention time (tr), 
and capacity factor (k') of the three components of polymyxin B (PB 1, PB2 and 
PB3) were recorded. The resolution between PB 1 and PB3 was also measured at each 
perchloric acid concentration. 
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2.2.5 Quantitative aspects - assay validation 
Using the solvent system containing 40:60 acetonitrile: aqueous 0.01 M DSHP , pH 
3.0 and 4.4 %w/v perchloric acid, the quantitative aspects and assay validation were 
carried out as follows. 
2.2.5.1 Linearity of detector 
The concentration of polymyxin B in commercial eye drops used in stability study 
"aries from 5.000 to 16,250 U/ml and the viscosity of the eye drops make it difficult 
to draw a sample for injection directly from the formulation. The concentration of 
polymyxin B, therefore, was determined by comparing the peak height of a 1: 1 0 
dilution of the formulation with that of a freshly prepared aqueous standard. 
Five concentrations of aqueous fresh polymyxin solutions were prepared ranging in 
concentration from 162.5 to 1625 U/ml. These concentrations were chosen since the 
estimated range of drug concentrations to be determined during proposed stability 
studies was from 1,625 to 16,250 U/ml. The peak height of each component was 
measured at 0.16 AUFS following injection of20 JlI of each concentration. 
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Since no extraction procedure is involved in this assay the accuracy of the method 
will be dictated largely by the specificity. The following procedures validate the 
specificity of the separation with respect to the other drugs and preservatives present 
in the fonnulations being detennined. The overall accuracy of the assay is also 
detennined by a standard addition method. 
1) Specificity with respect to other species 
Solutions of polymyxin B (16,250 Vlml), trimethoprim (0.1 %w/v), neomYCIn 
(0. 5 (%w/v), gramicidin (0.0025%w/v), benzalkonium chloride (0.004%w/v), 
thiomersal (0.005%w/v) and metaoxedrine (0.12%w/v) were prepared in water. 
Solutions were also prepared of polymyxin B (16,250 Vlml) combined with the 
above drugs at the following concentrations : trimethoprim (0.1 %w/v) , neomycin 
(0.5%w/v), gramicidin (0.0025%w/v), benzalkonium chloride (0.01 %w/v), 
thiomersal (0.005%w/v) and metaoxedrine (0.12%w/v). Since gramicidin is 
insoluble in water, the first solution of gramicidin was made in ethanol and diluted 
with water to get the required concentration. These solutions were injected and the 
retention time of polymyxin B and the other species were measured. 
2) Percentage recovery 
F our different eye drops fonnulations of sample 1,2,3 and 4 were spiked with known 
concentration of standard polymyxin B as the method described below: 
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2.1 Standard: Standard polymyxin B concentration 16,250 U/ml was prepared by 
the same method as described in 2.2.4.1 and further diluted ten times by water to 
produce the concentration 1,625 U/ml. 
2.2 Diluted eye drops : Eye drops were diluted ten times by water to get the 
concentration about 1,000 U/ml (sample 1), 500 U/ml (sample 2), 1,500 U/ml 
(sample 3), and 1,625 U/ml (sample 4). 
2.2 Diluted eye drops plus standard polymyxin B : 0.5 ml of standard solution 
(16,250 U/ml) and diluted eye drops were adjusted to 5 ml by water to achieve the 
concentration of polymyxin B in sample about 1,161.8 U/ml (sample 1), 661.8 U/ml 
(sample 2), 1,661.8 (sample 3) and 1,786.8 U/ml (sample 4). 
The concentration of PB 1, PB2 and PB3 of diluted eye drops plus standard were 
determined by comparing the peak height with diluted standard. The differences 
between assayed concentration and expected concentration were described in term of 
percentage accuracy. 
2.2.5.3 Precision 
The within day precision of the assay with respect to retention time and peak height 
was determined by dissolving 0.02 g polymyxin B (8090 U/mg) in water ( 16,250 
U/ml ) and diluting this solution 1 to 100 with water to provide the upper and lower 
concentrations expected during the proposed stability study. Replicate 20 JlI 
injections (10) of these solutions were made and the relative standard deviations of 
both retention times and peak heights for each of the polymyxin components were 
calculated. 
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'") '") - 1 L' . 
_._.).'"1" Imlts of detection 
An aqueous polymyxin sample of concentration 16,250 U/ml was made by the same 
method as described in 2.2.4.1. It was diluted and injected until the ratio of the 
height of the PB 1 peak to the baseline noise level was equal to 2.0. 
2.2.6 Chemical assay of polymyxin B eye drops 
Six selected commercial polymyxin B eye drops (sample 1-6, Table 2.7) were 
diluted ten times by water. The external standard concentration 16,180 U/ml was 
freshly prepared by dissolving 0.0200 g of polymyxin B sulphate (8090 U/mg) in 10 
ml of water and diluting ten times by water. Quantitative determination of 
polymyxin B in the eye drops was based on peak height comparison of PBl and 
PB2 of standard and samples. While it is accepted that this does not give absolute 
values of the concentrations of the individual components it allows comparisons 
among the different samples. Only PB 1 and PB2 were used as they clearly separated 
from the other components and were not affected by decomposition products [55]. 
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2.3 Results and discussion 
2.3.1 Separation development 
2.3.1.1 Effect of acetonitrile concentration 
The effects of altering acetonitrile concentration are summarised in Table 2.1 and 
Figure 2.1 Increasing acetonitrile concentration resulted in critically decreased 
retention time and separation of polymyxin B components. In system consisting of 
0.01 M DSHP, pH 3.0 and 0.2702 %w/v perchloric acid, changing acetonitrile 
concentration from 30 to 32 %v/v decreased retention time of peak PBl from 34 to 
15 minutes and the capacity factor which indicates separation was much decreased. 
The separation was strongly dependent on the concentration of acetonitrile in the 
mobile phase correlating with the results of earlier reports [5,48,52]. This finding is 
also consistent with the principle of reverse phase separation that changing the 
polarity of the mobile phase ( by increasing the ratio of organic solvent to water) 
will shift the distribution of solutes towards the mobile phase, and their retention 
will decrease [57]. The best separation ofPBb PB2 and PB3 from this mobile phase 
system was obtained at acetonitrile concentration 30%v/v but the retention times 
were still quite long ( 34, 29 and 20 minutes for PBb PB2 and PB3,respectively). 
Acetonitrile concentration 30 %v/v was used to investigate the effect of the other 
chromatographic variables. 
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Table 2.1 Effect of acetonitrile concentration on retention time and separation 
ACN(%v/v) 0.01 M tr ( min) Separation 
DSHP(%v/v) PB2 PB3 PB1 
tr value too 
50 50 - - 1.2 short, only 
PB1 
appeared. 
tr value too 
40 60 - 2.2 2.6 short, PB3 
too close to 
PB1· 
Three peaks 
32 68 9.5 13.0 15.0 were 
separated. 
30 70 20.0 29.0 34.0 The best 
separation 
Similar to 
28 72 25.0 38.0 45.0 30:70 but 
longer tr 
No peak 
25 75 - - - appeared 
after 1.4 h. 
-----------
45 -
40 -
35 -
-~ 30 -
-... 
.s 25 -(,,) 
~ 
-- --
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Fig. 2.1 Effect of acetonitrile concentration on capacity factor(k'). 
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2.3.1. 2 Effect of pH 
The effects of varying pH are summarised in Table 2.2 and Figure 2.2. Increase in 
pH from 2.0 to 2.8 resulted in decreased retention times of polymyxin peaks. In 
contrast, retention time was increased when pH was increased from 3.0 to 5.0. 
However, between pH 2.8 to 4.0, effect of pH was not critical and the capacity factor 
(k') of three major components were satisfactory (4.5 to 9.0). Therefore, the pH of 
the mobile phase should be adjusted within this range of pH. The pH of 3.0 as used 
before is thus suitable for this solvent system. 
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Table 2.2 Effect of pH on retention time (tr) and separation 
pH tr(min.) Separation 
PB2 PB l PB1 
2.0 11.0 16.0 19.0 Good separation 
(pH 2.0 -3.0) 
2.3 9.0 13.0 15.0 
2.5 6.5 9.5 11.0 
2.8 5.5 7.5 9.0 
3.0 5.6 8.2 9.6 
PB3 was close to 
3.6 5.5 8.0 8.5 PB1 
(pH 3.6 -4.4) 
4.0 5.5 8.5 10.0 
4.15 7.5 11.0 13.0 
4.4 9.0 12.0 14.5 
All peaks were 
5.0 10.0 16.0 18.0 not sharp and 
had bad shape. 
---- ---
18 -
16 -
14 --
-::.: 12 -
-... 
0 
-
10 -Co) 
~ 
~ 8 
Co) 
ca 6 --Q. 
ca 
0 4 _ 
2 _ 
0 _______ -+-1 ----+------ ----t---------------+---
1.5 2 2.5 3 3.5 4 4.5 5 
pH 
Fig. 2.2 Effect of pH on capacity factor(k'). 
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2.3.1.3 Effect of buffer concentration 
As seen in Table 2.3 and Fig. 2.3, the investigation of effect of buffer concentration 
was difficult because the wavelength of detection had to be increased due to the 
increased absorbance of DSHP at the higher concentrations. From the previous 
experiments, adequate separation was obtained from a system consisting of 30:70 
acetonitrile: aqueous 0.01 M DSHP, pH 3.0 and 0.2072 %w/v perchloric acid. At 
the higher wavelengths used PB2 and PB3 could not be detected. Although it was 
not possible to determine the effect of buffer concentration at wavelength 200 nm in 
this experiment, the overall data show that buffer concentration has little effect on 
the retention. 0.01 M DSHP is presumably the suitable concentration for this 
solvent system. 
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Table 2.3 Effect of buffer concentration on retention time(tr) and separation 
DSHP(M) 
PB2 
0.0050 16.0 
0.0075 10.0 
0.0085 -
0.0100 -
0.0115 -
0.0125 -
0.0150 -
0.0175 -
30 _ 
25 -
-~ 20 -
~ 
.s (,,) 
J! 15 -
~ 
(,,) 10 _ ns Q. 
ns 
0 
5 -
0------
0.0025 0.005 
---------
-- --
tr(min.) wavelength 
PB3 PB1 (nm) 
24.0 28.0 200 
16.0 19.0 200 
- 18.0 209 
- 16.0 210 
- 18.5 214 
- 15.0 214 
- 15.5 216 
- 14.0 218 
I ________ ~_ _ ________ +-----_ ------<C--------jl 
0.0075 0.01 0.0125 0.015 0.0175 
Buffer concentration (%w/v) 
-- - --- --_.-------
separation 
Three peaks 
were 
separated but 
not sharp. 
(0.0050-
0.0075) 
Only PB1 
appeared. 
(0.0085-
0.0175) 
-+-PB2 
____ PB3 
i-A--PB1 
Fig. 2.3 Effect of buffer concentration on capacity factor(k'). 
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2.3.1.4 Effect of perchloric acid 
Based on knowledge gained as to the effect of the variables acetonitrile 
concentration, pH and buffer concentration, a solvent system containing 28:72 
acetonitrile : aqueous 0.01 M DSHP, pH 3.0 was used to study the effect of 
perchloric acid on the separation. 28%v/v of acetonitrile was initially used since the 
lo\\"er ratio of acetonitrile would improve the separation of polymyxin B components 
as discussed in 2.3.1.1 and perchloric acid was another factor to increase the 
separation. From the previous data, the resolution between peak PBl and PB2 was 
usually appreciable at low concentrations of perchloric acid while peak PB3 was 
always close to PB 1. It was found that the presence of perchloric acid was 
important in increasing the resolution between peak PB 1 and PB3. Up to 
concentration 0.6000%w/v, the resolution between PBl and PB3 was not adequate 
and the retention time was still too long ( Table 2.4 a). To decrease retention time, 
acetonitrile was increased to 40%v/v and perchloric acid was then increased up to 
5.0%w/v ( Table 2.4 b). The best separation was obtained between 4.0 - 5.0%w/v 
perchloric acid as this range of concentration gave the highest resolution between 
PBl and PB3. In order to reduce the analysis time, the effects of concentration in 
the range 4.1 to 4.5%w/v were investigated further as shown in Table 2.4 c. In 
subsequent experiments in chapter 2, 3 and 9, a perchloric acid concentration of 
between 4.4 and 4.5 %w/v was used since this presented adequate resolution 
between components PB 1 and PB3 and gave the lowest obtainable analysis time. 
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Table 2.4 a Effect of perchloric acid concentration 0.0348 to 0.6000 %w/v on 
retention time(tr), separation and resolution of peak PB1 and PB3 
Mobile phase = 28:72 acetonitrile: aqueous 0.01 M DSHP, pH 3.0 
perchloric tr(min.) separation resolution 
acid(%w/v) PB2 PB3 PB1 PB1 and PB3 
0.0348 2.0 - 3.0 PB1 and PB2 
were eluted 
0.1849 5.0 6.5 7.5 PB1 PB2 and 
• 
PB3 were 
eluted but 
PB3 was 
close to PB1 
(0.1849 -
0.6000) 
0.2055 7.0 9.5 11.0 
0.2704 9.5 13.5 15.0 
0.4000 15.0 22.0 25.5 
0.5000 19.0 29.0 34.0 
0.6000 25.0 37.0 43.0 
------
-- --- -
60 -
50 -
-~ 40 
... 
-,-
0 
-
Co) 
ftS 30 
-
-~ 
.(3 
20 ftS 
--Q. 
ftS () 
10 -
o --~------- --~---------~---.------------~. ----" 
o 0.1 0.2 0.3 0.4 0.5 0.6 
Perchloric acid concentration (%w/v) 
-
-
-
0.5 
0.8 
0.71 
0.77 
--+--PB2 
___ PB3 
-.-PB1 
Fig. 2.4 a Effect of perchloric acid concentration 0.0348 to 0.6000 %w/v on 
capacity factor(k'). 
Mobile phase = 28:72 acetonitrile: aqueous 0.01 M DSHP, pH 3.0 
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Table 2.4 b Effect of perchloric acid concentration 2.0 - 5.0 %w/v on retention 
time and resolution of peak PB1 and PB3 
Mobile phase = 40:60 acetonitrile :aqueous 0.01 M DSHP , pH 3.0 
perchloric 
acid(%w/v) 
2.0 
3.0 
3.5 
4.0 
4.5 
5.0 
25 -
20 -
-~ 
0---
1.5 2 
tr(min.) 
PB2 PB3 PBi 
3.6 4.6 5.2 
4.8 6.4 7.4 
4.2 7.2 8.2 
6.4 9.0 10.6 
7.8 11.2 13.2 
9.8 14.4 17.6 
-r------- -~--,_____--. 
2.5 3 3.5 4 4.5 5 
Perchloric acid concentration (%w/v) 
resolution 
(PBi and PB3) 
1.6 
0.8 
1.5 
1.8 
1.67 
1.58 
!~PB2l 
-a- PB3i 
i-.- PB1 L _____ _ 
Fig. 2.4 b Effect of perchloric acid concentration 2.0 to 5.0 %w/v on capacity 
factor(k'). 
Mobile phase = 40:60 acetonitrile :aqueous 0.01 M DSHP , pH 3.0 
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Table 2.4 c Effect of perchloric acid concentration 4.10 - 4.50 %w/v on retention 
time(tr) and resolution of peak PB1 and PB3 
Mobile phase = 40:60 acetonitrile: aqueous 0.01 M DSHP , pH 3.0 
perchloric 
acid(%w/v) PB2 
4.10 5.9 
4.20 5.2 
4.30 5.4 
4.35 5.8 
4.40 6.0 
4.42 6.6 
4.46 7.0 
4.50 7.3 
16 -
14 -
-
12 
-
~ 
-a.. 10 -0 
-
CJ 
J! 8 -
~ 
6 -CJ ca 
c. 
ca 4 -0 
2 -
tr(min.) 
PB3 PB1 
6.6 7.6 
7.0 8.2 
7.4 8.6 
7.8 9.2 
8.4 10.0 
9.2 10.8 
9.8 11.6 
11.8 12.6 
resolution 
( PB1 and PB3) 
1.25 
1.50 
1.50 
1.33 
2.00 
2.00 
2.00 
2.13 
---
--+-PB2 i : 
1
'-II- PB3 
,-.-PB1 
I 
o ---- --+---- ----~---
Fig. 2.4 c 
factor(k') . 
4 4.1 4.2 4.3 4.4 4.5 
Perchloric acid concentration (%w/v) 
Effect of perchloric acid concentration 4.10 - 4.50 %w/v on capacity 
Mobile phase = 40:60 acetonitrile: aqueous 0.01 M DSHP , pH 3.0 
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'") ...., 1 - G 
-. -' . .) eneral conclusion 
Based on the data obtained from the investigation of these several chromatographic 
variables, the optimum mobile phase for the separation of polymyxin B components 
\vas 40:60 acetonitrile: aqueous 0.01 M DSHP, pH 3.0 and 4.4 %w/v perchloric 
acid. In this system, the use of high ratio of organic solvent (40%v/v) was necessary 
to prevent excessively long retention times. The effect of acetonitrile was critical 
and perchloric acid was the key factor for improving resolution. The effect of pH 
between 2.8 to 4.0 was not critical and buffer concentration had little effect on 
retention above 0.008M. By varying the concentration of perchloric acid, retention 
increased as the amount of perchloric acid increased. It was not clear how 
perchloric acid acts as ion pairing agent in this system. A possible mechanism of 
separation is that the polymyxin which is protonated at low pH forms ion pairs with 
perchlorate anions. The ion pairs behave as if they are non-ionic polar molecules, 
soluble in organic solvent. They are formed in the mobile phase and travel through 
the system as neutral species. Separation may occur by partitioning of these neutral 
ion pairs between the mobile phase and the C-18 [57]. 
This mobile phase allowed short analytical times (within 13 minutes for all three 
major polymyxin B components) and satisfactory degree of separation ( the 
resolution(Rs) of polymyxin B components was equal or more than 2). A specimen 
chromatogram of polymyxin B obtained using this mobile phase system is shown in 
Fig. 2.5. The quantitative aspects of the assay and their validation and when 
applying this solvent system to samples are discussed below in 2.3.2. 
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I 
" i; 
10 
Time/min. 
Fig. 2.5 Representative chromatogram of 16,250 U/ml polymyxin B using mobile 
phase containing 40:60 ACN : aqueous 0.01 M DSHP, pH 3.0 and 4.4 0low/v 
perchloric acid (chart speed = 0.2 em/min., 0.08 AUFS). 
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2.3.2 Quantitative aspects - assay validation 
2.3.2.1 Linearity of detector 
Least-squares regression of the three components peak height on total polymyxin B 
sulphate concentration (C ; D/ml) yield the following equations: 
Peak PB1 
Peak height (cm) - 936.8C + 0.9184 
Peak PB2 
Peak height (cm) - 197.1C + 0.1229 
Peak PB3 
Peak height (cm) = 165.2C + 0.0808 
( r2 = 0.9981 ) 
( r2 = 0.9994 ) 
( r2 = 0.9989 ) 
The relative standard deviation of slopes (RSD) of PB 1, PB2 and PB3 were 2.5, 1.4 
and 1.8 %, respectively. The high correlation coefficient and the small RSD show 
that the relationship between the peak height of these components and total 
polymyxin B concentration is linear although it is important to realise that the 
concentrations quoted refer to the total polymyxin and that these regression 
equations cannot be used directly to estimate individual polymyxin components. 
2.3.2.2 }\ccuracy 
Figure 2.6 is a composite chromatogram to show the retention pattern for the 
additional components and polymyxin. }\ll potential components of the eye drop 
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formulations other than neomycIn are eluted before the first polymyxin peak. 
Neomycin was eluted with a retention time very much greater than that ofPBl. 
Table 2.5 shows the results of the spiking procedure. The concentrations of 
polymyxin added to four formulations were found by determining the concentration 
in the formulation alone and after addition of a known concentration. These are 
shown in Table 2.5 expressed as percentages of the amounts added. These 
recoveries vary for different samples between 80.38 to 99.65 %. 
The stability indicating aspects of the specificity with respect to polymyxin i.e. the 
absence of interference by the products produced during decomposition has already 
been established by Taylor et al [55] and as recommended in that publication peak 
heights ofPB 1 and PB2 were used to determine polymyxin chemical stability. 
Table 2.5 Percentage accuracy of eye drop preparations spiked with standard 
polymyxin 8 
Sample Concentration of polymyxin added standard determined expressed as 
a percentage of the theoretical amount added 
PB2 PB3 PB1 
1 86.00 86.94 80.38 
2 94.10 94.75 96.74 
3 98.41 93.93 93.52 
4 90.09 99.65 99.76 
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Fig. 2.6 Chromatogram and retention times of polymyxin 8 and the other species 
in eye drops preparations ( ehart speed = 0.2 em/min., 0.08 AUFS ). 
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2.3.2.3 Precision 
The relative standard deviations of retention times and peak heights are shown in 
Table 2.6. The RSD for tr varies between 1.07 to 2.56 %. These values are higher 
than nonnal and may reflect the complex chromatographic system. The RSD for 
peak height are also high varying from 1.90 to 7.03. Both of these are considered 
to be adequate for the proposed stability study. The day to day precision was not 
evaluated since fresh standards were required to be prepared for quantification over 
an extended period of time. 
Table 2.6 RSD % of retention time and peak height at low and high concentration 
Polymyxin B conc.(U/ml) 
162.5 
16250 
PB1 
2.56 
1.07 
RSD % (tr) 
(n=10) 
PB2 
1.75 
1.63 
PB3 
2.26 
1.53 
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RSD% (Pk. Ht.) 
( n = 10) 
PB1 
5.83 
1.90 
PB2 PB3 
6.58 7.03 
2.77 2.23 
'1 ~ '1 I L·· f d . 
_.-'._.-t Imlts 0 etectIon 
The smallest concentration detected on the above criterion was 0.3236 Dim!. This 
represents a conservative limit of quantification in the region of 1 D/ml which is 
more than adequate for estimation of polymyxin B concentration during a stability 
study in which the anticipated concentrations will lie between 162.5 to 16,250 U/m!. _ 
The ruggedness of the method was investigated by changing variables slightly and 
examining the effects on retention time and peak heights. The results confirmed the 
information obtained during assay development that the critical parameter in the 
method was the proportion of acetonitrile in the mobile phase. The separation could 
tolerate appreciable alterations in the remaining chromatographic variables. 
2.3.3 Chemical assay of polymyxin B eye drops 
It is found that polymyxin B from different sources show different relative peak 
heights, for the different samples tested. This is demonstrated in specimen 
chromatograms shown in Figure 2.7. This is consistent with literature information 
[5,6,43,52]. From the eye drops assayed, polymyxin B can be subdivided into three 
groups according to the proportions of the individual components. The first group 
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comprises samples 1 and 2 which have the same proportion as the standard. The 
second group is sample 3 and the third group are sample 4, 5 and 6. 
Sample 
1 (Wel/come*) 
2 ( Seng Thai *) 
3 ( Dispersa*) 
4 (ALcon*) 
5 (Alcon*) 
6 (Alcon*) 
* Manufacturer 
** Preservative is not stated 
Table 2.7 List of samples 
Ingredient 
PMB 10,000 U/ml 
TMP 0.1% 
(Preservative: TMS 0.005%) 
PMB 5000 U/ml 
N 0.2% 
Gramicidin 0.0025%) 
** 
PMB 15,000 U/ml 
N 0.350/0 
(Preservative: BZK 0.01 %) 
PMB 16,250 U/ml 
N 0.350/0 
(Preservative: BZK 0.004%) 
PMB 16,250 U/ml 
N 0.35%) 
(Preservative: BZK 0.004%) 
PMB 16,250 U/ml 
N 0.35%) 
Phenylephrine hydrochloride 0.120/0 
(Preservative: BZK 0.004%) 
Sample 1,4 and 6 from U.K. Sample 2,3 and 5 from Thailand 
PMB = polymyxin B , TMP = Trimethoprim, TMS = Thiomersal , N = Neomycin 
BZK = Benzalkonium chloride 
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Table 2.8 shows the apparent concentrations of the individual components obtained 
by direct comparison of the corresponding peaks of sample and standard. These 
values show more clearly the differences in relative amounts of each component 
compared with the polymyxin used as standard. It can be seen that there is an 
apparent difference in correspondence between the labelled amount , based on 
microbiological assay and the chemical concentration of the individual molecular 
component as determined by comparison with the polymyxin standard. It is 
therefore of importance to investigate further means for the chemical determination 
of individual components. 
Table 2.8 Apparent Concentrations of polymyxin B mean ± S.D. according to the 
PB1 and PB2 measurements obtained from HPLC assay in eye drops 
sample labelled assayed concentration (U/ml) ; n =7 % labelled amount 
concentration PB1 PB2 PB1 PB2 
(U/ml) 
1 10,000 13,635.27 12,816.26 136.35 128.16 
(1711.14) (2178.71) (17.11) (21.78) 
2 5,000 6,332.92 5,954.48 126.66 119.09 
(1064.92) (890.97) (21.30) (17.82) 
3 15,000 6,273.42 36,859.17 41.82 245.73 
(744.58) (4079.12) (4.96) (27.19) 
4 16,250 15,997.50 75,365.33 98.45 463.79 
(1033.17) (6154.88) (6.35) (37.87) 
5 16,250 13,648.00 61,171.54 83.99 376.44 
(1862.63) (4599.45) (11.46) (28.30) 
6 16,250 14,647.75 63,699.38 90.14 391.99 
(2177.78) (5903.57) (13.40) (36.33) 
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Fig. 2.7 Representative chromatograms of polymyxin B eye drops assayed by 
developed mobile phase (chart speed = 0.02 cm/min., 0.08 AUFS). 
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2.... Conclusion 
The HPLC assay for the quantitative determination of polymyxin B in the eye drops 
in combination of other ingredients has been developed and validated. The proposed 
mobile phase for stability study should compose of 40:60 acetonitrile: aqueous 0.01 
M disodium hydrogen phosphate, pH 3.0 and 4.4 %w/v perchloric acid. This 
mobile phase allows short analytical time and the inclusion of perchloric acid 
improves the resolution and specificity of the polymyxin components. The 
disadvantage of this system is that concentration of perchloric acid has to be 
modified according to the column condition. The specificity of polymyxin B in the 
presence of other substances has been established and the use of this system for the 
stability determination of this drug in formulations has been validated. Additional 
work is required to allow quantification of individual components. 
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Chapter 3 
Chemical Stability Studies of Polymyxin B solutions 
3.1 Introduction 
This chapter describes accelerated chemical stability studies of polymyxin B in six 
commercial eye drops and polymyxin B alone in aqueous solution pH 6.0 using a 
developed stability-indicating HPLC method. It was intended to establish 
decomposition rate constants at elevated temperatures and estimate shelf-lives of test 
samples at low temperature (4°C). Three consecutive experiments were designed 
and performed to achieve suitable conditions for all samples. Tested temperatures 
included 32, 43, 50, 55, 60, 65 and 75°C. Temperatures higher than 60°C were not 
suitable for sample 2, 3 and polymyxin B alone as rapid decomposition of 
polymyxin B in these samples occurred. The effect of container, the duration of 
sampling and the duration of study were also tested. The original containers and 
plastic vials were used in the first and second experiment and it was found that there 
was some leaking of samples especially at high temperatures. The most suitable 
procedure is described below: 
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3.2 Methods 
Chemicals and reagents, apparatus and chromatographic conditions were as 
described in Chapter 2. 
The standard aqueous solution was prepared by dissolving 0.20 g of polymyxin B 
sulphate (8090 U/mg) in 100 ml phosphate buffer pH 6.0 ( see chapter 4 for 
preparation ) to give a concentration of 16,250 U/ml and diluting ten times with 
HPLC water to give 1625 U/ml. The diluted standard solution was then transferred 
to 10 ml plastic vials and frozen. 
Phosphate buffer pH 6.0 was used since it is recommended in the BP[44] to be used 
as a solvent for polymyxin B. It is also important for stability reasons to maintain 
the pH of polymyxin B solutions stored in glass containers especially at high 
temperatures. 
Test samples were six selected commercial polymyxin B eye drops all have original 
pH range between 5.41 to 6.92 ( sample 1-6, Table 2.7 , see Table 9.3, chapter 9 for 
the pH of each sample ) and polymyxin B solution concentration 16,250 U/ml 
(PMB) prepared by the same method as standard solution. They were stored in 
completely closed volumetric flasks in 43** ,50* ,55* and 60*oC thermostatted ovens 
for a period of 500 h ( ** = normal oven, * = GLC oven). The samples were not 
stored in their original packages as the preliminary stability study showed that there 
was some leaking of the solutions from the containers during storage at high 
temperatures. 
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Samples were withdrawn from the stored preparations at appropriate intervals for 
assay. When taking measurements, an individual standard solution vial was 
removed from the freezer, thawed and injected into the HPLC system. Samples 
\vere removed from the heat sources and cooled immediately under running tap 
water for a few minutes. They were diluted ten times by HPLC water and injected 
into HPLC system. All dilutions were kept at room temperature and analysed 
\yithin 8 h. At least triplicate injections of the standard solution were made to 
ensure the reproducibility of results. Each sample was injected once and compared 
\yith the nearest standard. The results were based on the comparison of the 
percentage peak height remaining of PB 1 and PB2 in the samples during 
decomposition relative to the original peak height produced by the standard. 
Possible interference of the decomposition products of the other antibacterials and 
preservatives in formulations was tested by placing eye drops concentration of 
aqueous solutions of trimethoprim, neomycin, gramicidin, benzalkonium chloride, 
thiomersal and metaoxedrine ( 0.1 %w/v, 0.5%w/v, 0.0025%w/v, 0.004%w/v, 
0.005%w/v and 0.12O/ow/v, respectively) stored in volumetric flasks in 55°C GLC 
oven during the time of study. They were taken from the stored solutions, diluted 
ten times with HPLC water and then injected into HPLC system at the same time as 
the other samples. 
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3.3 Results and discussion 
3.3.1 Temperature profiles 
The chemical stabilities of all samples at 43, 50, 55 and 60°C are represented by 
plotting the natural logarithm of the percentage remaining of PB I and PB2 at each 
temperature against time ( Fig. 3.1). As the degradation pattern of PB2 is similar to 
PB I . only PB I plots are demonstrated. Since the decomposition of polymyxin B in 
aqueous solution follows first - order kinetics [55], the decomposition rate constants 
at each temperature were calculated from the plots based on equation (1) [58]. 
In[C] - In[Co] - kt (1) 
Where the initial concentration of polymyxin B IS [Co], the time-dependent 
concentration is [C] and time is t. 
The calculated decomposition rate constants are shown in Table 3.1. 
The data indicate that there was no significant degradation ofPB I and PB2 in sample 
1, 4, 5 and 6 at all accelerated temperatures over this duration of storage. The rate 
constants estimated from the regression equations of these samples were not reliable 
because they were stable in these temperatures and the study time period was too 
short to accurately estimate small decomposition rate constants. 
In contrast, regressIon analysis of sample 2, 3 and polymyxin B alone for all 
temperatures showed significant time - dependent changes in the percentage 
remaining of PB I and PB2. The correlation coefficients of the plots increased as the 
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temperature increased. The overall results show that sample 1, 4, 5 and 6 were 
more stable than sample 2, 3 and polymyxin B alone in aqueous solution pH 6.0 ( 
PMB ) under the conditions for this study. 
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Fig . 3.1 First-order plots of PB1 in sample 1-6 and polymyxin B aqueous solution 
pH 6.0 (PMB) after storage at 43, 50, 55 and 60°C for 500 hours. 
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Table 3.1 Decomposition rate constants of the main components of polymyxin B in sample 1-6 and PMB at 43, 50, 55 and 60°C 
"'''''''''''''''''''''''''''''' .. , ' ..... ,-..... ' ' .... '', .... ''-,~~~-_ ..... ''''''' ... :-.'''"' ....... ,"""'''''''''''''''''''''''''''''''''''''''''''''''', ..... '''''' .......... ,'''''", ..... "'" ..... """" ... "'''' ........ "", .. '''...,.,.., .......... "''' .. ", .. , .... _v,,,, ........ ''',,,,'''''' _____ .... "' ... _",.. ..... """' __ ~. , ..... ,"""''"' ... __ ~ ....... _..,.... .',W ____ H"-"'.'//>W_,.,H;. ". "' .... """",_ ..... ###""NHN ... N~ .... "" .. "# .. //N~/""N_N ... NN"'NN/~H .. H ___ ____ 
Sample 
.... """" .. ", ... , .. ," ..... " .. -- ..... 
43°C 50°C 
PB1 PB2 mean PB1 PB2 
1 -0.461 -1.656 -1.059 1.661 2.785 
(0.0061) (0.0835) (0.1013) (0.3275) 
2 3.173 0.973 2.073 5.489 5.098 
(0.2927) (0.0600) (0.5403) (0.1703) 
3 11.421 11.953 11.687 15.010 16.910 
(0.6561) (0.8578) (0.7355) (0.8889) 
4 1.647 1.285 1.466 -0.266 -0.067 
(0.0606) (0.0530) (0.0025) (0.0002) 
5 0.456 1.753 1.104 0.381 0.148 
(0.0147) (0.1880) (0.0119) (0.0015) 
6 -1.559 -0.129 -0.844 -0.450 0.487 
(0.0564) (0.0005) (0.0127) (0.1095) 
PMB 10.596 8.667 9.632 13.497 11.938 
(0.4881) (0.4278) (0.6022) (0.7009) 
R2 = correlation coefficient of the first order plots 
Rate constant: h'1 x 104 
( R2) 
mean PB1 
2.223 4.553 
(0.6758) 
5.489 21.329 
(0.9095) 
15.960 60.575 
(0.9151) 
-0.167 3.674 
(0.4084) 
0.264 3.286 
(0.6112) 
0.0185 3.957 
(0.4536) 
12.718 49.426 
(0.9367) 
_'<1"""""""""';"\)"" 
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55°C 
PB2 mean 
5.164 4.859 
(0.6377) 
14.325 17.827 
(0.4557) 
70.431 65.503 
(0.9713) 
4.281 3.977 
(0.3997) 
4.103 3.694 
(0.7485) 
3.639 3.798 
(0.4014) 
43.249 46.338 
(0.8849) 
PB1 
4.887 
(0.5404) 
42.716 
(0.9839) 
128.486 
(0.9970) 
-0.270 
(0.0014) 
3.239 
(0.2979) 
4.824 
(0.2611) 
78.311 
(0.9137) 
60°C 
PB2 
4.007 
(0.4470) 
34.731 
(0.9162) 
136.962 
(0.9750) 
7.399 
(0.091) 
3.398 
(0.3579) 
3.442 
(0.1576) 
74.257 
(0.8837) 
mean 
4.447 
38.724 
132.724 
3.565 
3.318 
4.133 
76.284 
"W'·"''''''.''S$'.''~''''''''''-''''''''''''''' ____ ~ 
3.3.2 The interference of decomposition products of other antibacterials and 
preservati ves 
It was reported earlier that the HPLC method used in this study was specific to 
identify PB 1 and PB2 from the decomposition products of polymyxin B itself and 
from other antibacterials and preservatives in eye drop formulations. The 
interference of the decomposition products was also tested in this study. No 
additional HPLC peaks were noted in stored samples at the same retention times of 
PB 1 or PB2 after storage at 55°C for 500 h. It can be concluded that the interference 
of both these substances and their decomposition products was avoided. 
3.3.3 Shelf-life determination 
The effect of temperature on the rate of decomposition may be described by an 
equation (2) proposed by Arrhenius [58]. 
Ink = InA - EaJR T (2) 
where k is rate constant, A is frequency factor, Ea is the activation energy, R is the 
gas constant ( equal to 8.314 Jmorl K-1 ) and T is absolute temperature. 
Once the rate constant at 4°C is obtained by extrapolation from Arrhenius plot, the 
shelf-life (190) can be calculated using equation (3) [58]. 
190 = 0.1 05/k (3) 
where k is the observed first order rate constant at 4°C. 
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Only the data from sample 2, 3 and polymyxin B alone (PMB) were reliable to 
determine shelf-life (t90)' The activation energy (Ea) of polymyxin B in sample 2, 
3 and PMB were estimated from slope of the Arrhenius plots of the data obtained at 
accelerated conditions ( Fig. 3.2 a). The decomposition rate constants used in the 
plots 'yen:~ an average of decomposition rate constants of PB I and PB2. All plots 
show good linearity. Estimated Ea of polymyxin B in sample 2, 3 and PMB were 
154.37. 132.44 and 114.24 kJmor l, respectively. They were all higher than that 
calculated by Taylor et al [55] which was 64.8 kJmorl. The estimated shelf-lives 
from this study and those obtained from Taylor et al and Dreyer van der Glas et al 
[56] are shown in Table 3.2. 
The ~o at 4°C of polymyxin B in these three samples were much higher than the 
previous studies especially polymyxin B alone in buffer pH 6.0 which was nearly 
20-times greater than Taylor's value. Similar to Taylor's study, ~o estimation was 
based on extrapolation from the measurement of polymyxin B at elevated 
temperatures but with higher temperatures. The t90 from these two studies should 
be similar. The higher ~o of polymyxin B in these samples may result from the 
higher temperatures used. The high temperatures may cause the breakdown of the 
main components ( PB I and PB2 ) and produce the small amount of decomposition 
products underneath these two peaks which could be detected by HPLC at the same 
time as the original PB I and PB2. This suggestion correlates to the chromatograms 
of all decomposed samples at the end of the experiment which were similar to the 
original except the decreasing of peak height of PB I and PB2· The high 
temperatures may also affect degradation mechanism of polymyxin B. As 
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mentioned by Pearlnlan and Nguyen [59] that extrapolation of stability data of 
protein drugs to lower temperatures should be limited to the temperature range over 
\\'hich the same degradation pathway is operative. Arrhenius approach should be 
conducted in the temperature range below 40°C. Polymyxin B, as a decapeptide 
drug. may be considered to have similar properties to some of protein drugs which 
degradation mechanisms have been reported to vary as a function of temperature. 
As there are no reports in the literature regarding degradation mechanism of 
polymyxin B, this suggestion cannot be excluded. Another possible reason may 
result from the effect of the other ingredients added in the formulations. 
Both this study and that of Taylor et al [55] study obtained good correlation between 
decomposition rate constant and temperature of polymyxin B alone in aqueous 
solution pH 6.0. Arrhenius plots of two set of data as shown in Fig 3.2 b also 
demonstrate an acceptable correlation coefficient. The estimated Ea was 81.80 
kJmorl. The ~o at 4°C extrapolated from the plots was about 312 days or 10 
months. This ~o was more reliable than the t90 estimated from this study and this 
may indicate that the extrapolated t90 would be more accurate if an increased number 
of temperatures are used. 
Dreyer van der Glas et al [56] also studied chemical stability of polymyxin B in eye 
and ear drops. Different methods and different samples were used. Polymyxin B 
content in samples stored at -18, 4 and 21°C was analysed by HPLC for a period of 
25 months. The ~o values were estimated when polymyxin B content dropped to 
90%. The disadvantage of this method is that the measurement of drug content 
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during a long period of time may cause the variability of the results. The ~o 
obtained was much lower than those obtained from this study and Taylor et al. 
Taylor and Shivji [60] suggested that in order to estimate decomposition rate 
constant and subsequently shelf-life, it is necessary to decompose the drug by 75 
percent. 
While it is accepted that extrapolation from higher temperatures has advantages over 
direct measurement at storage temperatures due to the long time scales required for 
the determination of decomposition rate constants, it is important to choose suitable 
temperatures and stability indicating methods of analysis. In this study the both 
factors were carefully chosen. However, the extremely high t90 when they were 
applied to polymyxin B samples indicate that both have to be modified. In the case 
of polymyxin B formulations where the original drug is combined with many 
ingredients, it is very difficult to find the most suitable stability study method for all 
samples. 
Although these three stability studies obtained different t90 values of polymyxin B, 
there is a good agreement on the effect of pH on the stability between two studies. 
Taylor concluded that, at 37°C, below pH 7, pH has little effect upon the 
decomposition but above this value, increase of pH markedly accelerates the 
reaction. This is consistent with Dreyer van der Glas' s findings which showed that 
at 21°C, percentage remaining of polymyxin B formulated at pH 7.1 significantly 
decreased from 100% to about 30% within 15 months but those formulated at pH 4.7 
and 6.6 remained higher than 90% over a period of20 months. 
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Table 3.2 Estimated shelf-life (tgo) of polymyxin B at 4°C 
Sample t90 at 4°C ( day) 
1) This studt 2) Tay/oretat 1) and 2) 3) Dreyer et af 
2 90570 - - -
3 5878 - - -
polymyxin B 
new -
- - 540 
formulationd 
polymyxin B 
alone in 2544 130 312 -
aqueous 
solution pH 
6.0 
a estimated from accelerated stability study of at 43, 50, 55 and 60°C, samples were made up in 
phosphate buffer pH 6.0. 
b estimated from accelerated stability study at 32, 37, 43 and 52°C, sample were made up in 
disodium hydrogen phosphate buffer (50 mM) , pH 6.0. 
C estimated by storage polymyxin B formulation at 4°C over a period of 25 months. 
d Polymyxin B sulphate 1,000,000 Units, Borax 60 mg, Boric acid 1.95 g, Benzalkonium chloride 10 
mg, Sodium acetate 100 mg and Sterile water to 100 ml. 
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0 
-1 
-2 
-3 
::'" 
-4 
s= 
-JiI: 
-5 
.5 
-6 
-7 
-8 
-9 
0.003 
0 
-1 
-2 
-3 
-
-. 
s= 
-4 
-JiI: 
.5 
-5 
-6 
-7 
-8 
a) 
0.00305 0.0031 0.00315 0.0032 0.00325 0.0033 
• Sarll'le 2 
• Sarll'le 3 
A Pf\.e 
Sarll'le 2 
Ink = -18567fT + 50.183 
~=0. 9878 
Sarll'le 3 
Ink = -15930fT + 43.398 
~=0.9075 
Pf\.e 
Ink = -13741fT + 36.331 
1fT ( K-1) ~ =0.9029 
b) 
0.00305 0.0031 0.00315 0.0032 0.00325 0.0033 
1fT (K-1 ) 
Ink = -9838.5/T + 24.341 
~= 0.8993 
Fig . 3.2 Arrhenius plots of sample 2, 3 and PMB using data from this study a) 
and combined data of PMB from this study and Taylor et al b). 
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3.4 Conclusion 
The stability studies of the chemical stabilities of the main components of 
polymyxin B were carried out using standard material in aqueous solution and the 
six samples of the formulated eye drops. High Performance Liquid 
Chromatography (HPLC) was used to quantify the amount of the main components 
left during accelerated stability studies without absolute concentrations being 
determined. This stability indicating method allowed rapid determination of 
polymyxin B in aqueous solution without the interference of the decomposition 
products or of other antibacterials and preservatives in the eye drops. The data 
indicate that there are significant differences in chemical stability among the 
different formulated eyedrops. The exact reasons for this are not clear at present. 
The elevated temperatures used in this study were not suitable for all samples. The 
accurate decomposition rate constants and shelf-lives (~o) at 4°C of sample 2, 3 and 
polymyxin B alone in aqueous solution pH 6.0 stored in glass containers in which 
rapid decomposition process occurred were established. The combined data from 
this study and Taylor et al [55] both carried out in elevated temperatures shows 
significant correlation of decomposition rate constants of polymyxin B in aqueous 
solution pH 6.0 and temperature in the range of 32 to 60°C. Shelf-life estimation 
from this study yielded higher ~o value than those obtained in previous studies 
which may result from the higher temperatures used and the effect of other added 
ingredients in the formulations. Further investigations on the degradation 
mechanism of polymyxin B at various temperature and also the effect of other 
substances in the formulations on the stability of polymyxin B are needed. The 
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differences between decomposed samples in terms of microbiological activity which 
\vill be used to correlate with chemical stability data is described in chapter 9 and 10. 
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Chapter 4 
Materials and microbiological methods 
This chapter describes materials and microbiogical methods used in the following 
chapters. 
4.1 Materials 
4.1.1 Chemical and reagents 
The distilled water used in the microbiological experiments was prepared using a 
glass still Model A45, Aquatron Ltd.. Polymyxin B sulphate (PMB), trimethoprim 
(TMP), neomYCIn (N), gramicidin (G), metaoxedrine or phenylephrine 
hydrochloride (M), benzalkonium choride (BZK), lecithin and sodium hydroxide 
were obtained from Sigma. Thiomersal was purchased from Aldrich Chemical. 
Magnesium sulphate and potassium dihydrogen phosphate were supplied by Fisons 
Scientific Apparatus, Loughborough, Leics, UK. Polysorbate 80 was purchased 
from BDH Laboratory Supplies. Polymyxin B eye drops were purchased from 
Wellcome ( sample 1 ), Seng Thai (sample 2 ), Dispersa ( sample 3 ) and Alcon ( 
sample 4, 5 and 6 ). 
( see Table 2.7, chapter 2 for detail) 
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Phosphate buffer pH 6.0 was used as the solvent for the test substances and was 
prepared by the method described in the European Pharmacopoeia [61] by mixing 
50.0 ml of 0.2 M potassium dihydrogen phosphate with 5.70 ml of 0.2 N sodium 
hydroxide. Distilled water was added to produce 200.0 ml. 
.... 1.2 Media 
-+.1. '1.1 Nutrient agar 
Nutrient agar ( *Oxoid. Basingstoke, Hampshire, UK ) prepared as slopes was used 
to maintain the viability of stock cultures. Slopes were separately inoculated with 
broth culture of each test organism, incubated for 24 h at 37°C and then stored at 2-8 
DC. The slope cultures were used as the source of inoculum for each experiment. 
Fresh slope cultures were prepared every 4 weeks. 
Nutrient agar was also used as the growth medium for determining the number of 
colony-forming units ( CFU). See chapters 7 to 9. 
The formula is : "Lab-Lemco" Powder 1.0 g 
Yeast Extract 2.0 g 
Peptone 5.0 g 
Sodium chloride 5.0 g 
Agar 15.0 g 
Distilled water to 1000 ml 
pH 7.2 - 7.6 
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The nutrient agar was prepared by suspending 28 g in 1 I of distilled water and 
bringing to the boil until the granules were dissolved completely. Sterilization was 
by autoclaving at 121°C for 15 min. 
4.1.2.2 Medium B agar 
Medium B agar [43 ] is a specialist medium for culturing Bordetella bronchiseptica 
NCTC 8344. 
The formula is: Pancreatic digest of casein 17 g 
Papaic digest of soya bean 3 g 
Sodium chloride 5 g 
Dipotassium hydrogen orthophosphate 2.5 g 
D-glucose 2.5 g 
Agar 15g 
Polysorbate 80 10 g 
Distilled water to 1000 ml 
The agar was prepared by dissolving all the ingredients in 1 L of distilled water and 
bringing to the boil until the granules were dissolved completely. The polysorbate 
80 was added to a hot solution of the other ingredients. Sterilization was by 
autoclaving at 121°C for 15 min. 
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-+.1.2.3 Nutrient broth 
Oxoid* nutrient broth was used for culturing P. aeruginosa NCTC 6750. The 
formula and the directions for preparation are the same as for nutrient agar except 
that there is no agar. 
4.1.2.4 Thioglycollate broth 
Oxoid* thioglycollate broth USP alternative was used as inactivating medium for 
thiomersal. Magnesium sulphate and p-aminobenzoic acid (PABA) concentration 
1 % and 0.16 % respectively were added for the inactivation of polymyxin Band 
trimethoprim, respectively. 
The formula is : L-cystine 
Sodium chloride 
Glucose 
Yeast extract 
Pancreatic digest of casein 
Sodium thioglycollate 
Distilled water to 
pH 6.9 - 7.3 
0.5 g 
2.5 g 
5.5 g 
5.0 g 
15.0 g 
0.5 g 
1000 ml 
The broth was prepared by suspending 29 g of granules in 1 I of distilled water and 
bringing to the boil in order to dissolve the medium completely. Sterilization was 
by autoclaving at 121°C for 15 min. 
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~.1.3 Test organisms 
Bordetella bronchiseptica NCTC 83-1-1 and Pseudomonas aeruginosa NCTC 6750 
were obtained from the National Collection of Type Cultures, Public Health 
Laboratory Service, Colindale Avenue, London NW9. 
~.1.~ Apparatus 
R Autoclave (Dataclave ) 
Bench autoclave 
Centrifuge (lEC Centra-4B ) 
Water bath 
Southtrim Autoclave Limited 
Valley Road Bradford, West Yorkshire 
BD 1 ARJ England 
Adelphi Manufacturing Co. Ltd. 
20/21 Duncan Terrace 
London Nl 887, England 
International Equipment company 
Grant Instruments Ltd. 
UV NIS Spectrophotometer ( Model SP8-400 ) Cecils Instruments 
Membrane filters 0.2 J.lm pore size ( AerodiscR PF) Gelman Sciences 
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4.2 Microbiological methods 
-t2.1 Microbiological assay 
4.~.1.1 Inoculum preparation 
B. bronchiseptica NCTC 8344 was incubated at 37°C overnight on an agar plate of 
medium B. A suspension of the test organism was prepared by washing the growth 
off the nutrient agar and diluting with normal saline solution to give an opacity of 
0.20 at 500 nm. It was further diluted to prepare a suspension having approximately 
107 CFU/ml. 
4.2.1.2 Assay procedure 
Molten medium B was added to petri dishes in 20 ml quantities and inoculated with 
0.1 ml of B. bronchiseptica suspension (107 CFU/ml) at a temperature not 
° exceeding 50 C. When the agar was set, wells were cut and the plugs removed. 
The test solutions were introduced to the wells and the dishes were maintained at 
room temperature for about 2 h to allow diffusion of the solutions into the agar. 
° After incubation at 37 C for 18 h, the diameter of the zones of inhibition was 
measured in 3 directions. 
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.. 1..2.2 Killing time determinations 
4.2.2.1 Inoculum preparation 
A sample of a slope culture of P. aeruglnosa NCTC 6750 was inoculated into 
nutrient broth and incubated at 37°C for 18 h. The 18 h cultures were centrifuged ( 
4000 g, 10 min). The cell pellets were washed in 0.9% sodium chloride ( NSS ), 
recentrifuged for 5 min and resuspened in 4 ml NSS. 
4.2.2.2 Procedure for determining microtitre counts 
The following procedure was used in 7.2.3 , chapter 8 and chapter 9. 
Standard solutions of polymyxin B were freshly prepared by dissolving 0.0131 g of 
polymyxin B sulphate (7760 Vlmg) in 10 ml of phosphate buffer pH 6.0 to produce 
a concentration of 10,000 Vlml. Further dilutions were made using phosphate 
buffer pH 6.0 to produce concentrations of 5000, 4000, 2000, 1000, 500, 250 and 
125 Vlml. When 4000 Vlml was needed, a standard solution was prepared by 
dissolving 0.0131 g polymyxin B in 25 ml of solvent. These solutions were 
sterilized by filtering through 0.2 J.l membrane filters. The subsequent procedure 
was similar to that described by Richards and Xing [62]. AlSO J.lI volume of each 
standard solution was mixed with 150 J.lI of cell suspension in the first row 
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( designated N ) of a microtiter plate to yield final concentrations of '" 1 08 - 1 09 CFU 
per ml. The wells in row 1-6 of the microtiter plate were primed with 200 J..lI of 
appropriate inactivating recovery medium, and 10 J..lI samples from row N were 
added to row 1 and diluted through six serial 20-fold dilutions by adding 10 J..lI 
samples from row 1 to row 2, from row 2 to row 3 and so on to row 6. Each dilution 
was plated in triplicate on overdried nutrient agar for counting. Samples were 
thoroughly mixed by being drawn into a pipette tip and expelled four times before 
either being plated for counting or being diluted further. At the contact times of 10, 
20. 30,-+0.50 and 60 mIn. 10 J..lI samples were transferred and diluted through 
another set of rows 1-6. Samples of each dilution were again transferred to 
overdried nutrient agar plates in triplicate and incubated at 32°C for 15 h. The 
number of CFU per 10 J..lI were detennined for each sample. The highest countable 
number of CFU per 10 J..lI ( 15-30 CFU ) for each series of dilutions was the count 
recorded. The number of CFU per milliliter was calculated for each row of 
dilutions, i.e. neat 10 J..lI drop, number of colonies times 102; row 1, number of 
colonies times 2 x 103, etc., to row 6, number of colonies times 6.4 x 109. The 
lower limit of sensitivity of the counting method was 103 CFU/ml. Cell 
suspensions ( 150 J..lI ) mixed with either water or phosphate buffer pH 6.0 ( 150 J..lI ) 
were used as the controls. The killing curves were plotted from log CFU/ml of 
P. aeruginosa against time. The dotted lines represented the concentration of the 
test bacteria below the detection limit of sensitivity (103 CFU/ml). The standard 
deviation (SD) of each count was also calculated. SD of some figures were omitted 
from the graphs in order to clarify the killing curves. 
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Chapter 5 
Effect of added ingredients in polymyxin B eye drops on 
B. bronchiseptica NCTC 8344 
5.1 Introduction 
The compendial methods of quantitative analysis for polymyxin B in the British, 
European and United States Pharmacopoeias are currently microbiological 
[~4,61.63]. The suggested method in the British Pharmacopoeia is by using the agar 
plate diffusion method which is suitable for polymyxin B alone. However, the 
selected polymyxin B eye drops contain other ingredients which may affect the 
growth of the test organism. F or example the six eye drop formulations of 
polymyxin B contain one or more of the following antibacterials ; 0.1 %w/v 
trimethoprim, 0.35%w/v neomycin , 0.0025%w/v gramicidin and either of the 
following preservatives; 0.01 % or 0.004%w/v benzalkonium chloride or 0.005%w/v 
thiomersal. In addition one preparation contains 0.12%w/v metaoxedrine 
(phenylephrine hydrochloride). Therefore the effect of these substances on the 
inhibition of the test organism was investigated using the same agar plate diffusion 
method as for determining the potency of polymyxin B eye drops. 
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5.2 Methods 
Inoculum preparation and assay procedure were as described in 4.2.1. except that 
preparation and distribution of the test solutions in the wells were as follow: 
Preparation of test solutions: 
The solutions of polymyxin B combined with each of the other ingredients were 
made in phosphate buffer pH 6.0 at the appropriate concentrations. For the 
polymyxin B plus trimethoprim solution, 1 0% of 0.05 M of lactic acid was used to 
increase the solubility of trimethoprim. For gramicidin which is insoluble in water, 
the highest concentration made in a mixture of water and ethanol was 0.00008 
%w/v. Therefore only dilute concentrations of gramicidin (0.00001 to 0.00008 
%w/v) were investigated. Eye drop concentrations of polymyxin B plus the other 
substances were then diluted accordingly to provide the concentrations of polymyxin 
B used in the microbiological assay (160, 80, 40 and 20 Vlml). These were chosen 
from the determinations of the diameter of the zones of inhibition produced by 
polymyxin B concentrations ranging from 2.5 to 160 Vlml. The log concentration 
range from 20 to 160 Vlml plotted against the diameters of their zones of inhibition 
gave a straight line ( Fig. 5.1 ). A transformation of concentration to log 
concentration is necessary to achieve a linear relationship. This range of 
concentration is within the recommended potency of polymyxin B suitable for 
microbiological assay [44]. 
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Fig. 5.1 Plot of log concentration and inhibition zone diameter of polymyxin B 20 to 160 
U/ml against B. bronchiseptica NCTC 8344 
The distribution of the test solutions in the wells were as follows: 
Trimethoprim. neomycin. benzalkonium chloride,metaoxedrine and thiomersal 
Dishes Solutions 
1 1 6 11 2 7 
, 2 7 12 3 8 
3 3 8 13 4 9 
4 4 9 14 5 10 
5 5 10 15 1 6 
The number of the test solutions indicating the concentrations used are given in Tables 5.1-5.4. 
Gramicidin 
Dishes Solutions 
1 1 6 11 16 
2 2 7 12 13 
3 3 8 9 14 
4 4 5 10 15 
The number of the test solutions indicating the concentrations used are given in Table 5.5. 
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12 
13 
14 
15 
11 
0 
0 
0 
0 
The effect of preservatives and the other ingredients in polymyxin B eye drops on B. 
bronchiseptica was investigated. Trimethoprim, neomycin, benzalkonium chloride, 
thiomersal, metaoxedrine ( L - phenylephrine hydrochloride) and gramicidin are 
contained in the various polymyxin B eye drops at the following concentrations ; 
0.1 %w/v trimethoprim (sample 1), 0.35 %w/v neomycin (samples 2, 3, 4, 5 and 6 ), 
0.004 %w/v benzalkonium chloride (samples 4, 5 and 6), 0.01 %w/v benzalkonium 
chloride (sample 3). 0.005 %w/v thiomersal ( sample 1 ), 0.12 %w/v metaoxedrine ( 
sample 6 ) and 0.0025 %w/v gramicidin ( sample 2). In the microbiological assay 
of polymyxin B. the eye drops were diluted to achieve concentrations of 20, 40 and 
80 U/ml of polymyxin B. The inhibition zone diameters of these dilutions were 
then compared with the inhibition zone diameters of freshly prepared standard 
solutions of polymyxin B at the same concentrations. 
In this experiment, eye drop concentrations of test substances were prepared and 
diluted to the same dilutions as the polymyxin B eye drops. The inhibition zone 
diameters of the solutions were measured and compared with standard solutions of 
polymyxin B. 
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5.3 Results and discussion 
Trinlethoprim 
Table 5.1 shows that inhibition zones were produced by 0.1 % wlv trimethoprim 
(concentration in the eye drops). Trimethoprim 0.1 % wlv combined with 
polymyxin B 10,000 Vlml also produced inhibition zones which were significantly 
different from those produced by polymyxin B 10,000 Vlml ( t - test, p = 0.05). In 
contrast, there was no significant differences between the inhibition zones of 
polymyxin B alone and polymyxin B plus trimethoprim in dilute concentrations (t -
test, p = 0.05). It can be concluded that trimethoprim 0.1 %w/v addded to the 
antibacterial activity of polymyxin B 10,000 Vim!' When this combination was 
diluted to give concentrations of polymyxin B of 160, 80, 40 and 20 Vlml, then the 
diluted trimethoprim did not add to the inhibition zone diameter of polymyxin B. 
Thus trimethoprim at these dilute concentrations would not adversely affect the 
biological assay of polymyxin. 
Neomycin 
The data in Table 5.2 shows that 0.5 % wlv neomycin produced inhibition zones 
against B.bronchiseptica and the inhibition zone diameters of 0.5 % wlv neomycin 
plus polymyxin B 16,250 Vlml ( concentration in eye drops ) were significantly 
different from those produced by polymyxin B alone 16,250 Vlml ( t - test, p = 0.05 
). That is neomycin added to the effect of polymyxin B at the concentrations used 
in the eye drops. However, the dilute concentrations of neomycin had no effect on 
B. bronchiseptica in medium B and the inhibition zones from diluted concentrations 
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of neomycin plus polymyxin B were no different from those of polymyxin B alone ( 
t - test. p = 0.05). Consequently, these dilute concentrations of neomycin can be 
used in the biological assay of polymyxin B without influencing the inhibition 
zones. 
Benzalkonium chloride and metaoxedrine 
The results are summarised in Table 5.3. Benzalkonium chloride 0.004 %w/v had 
no effect and the combination of benzalkonium chloride 0.004 %w/v with 
polymyxin B 16.250 U/ml showed no significant difference from the effect of the 
polymyxin B alone. This indicates that benzalkonium chloride at concentrations 
below 0.004 %w/v did not have antibacterial activity against B. bronchiseptica and 
\\"ould not interfere with the biological assay of polymyxin B. 
Similar results were obtained with metaoxedrine. The eye drop concentration of 
metaoxedrine produced a small inhibition zone against B. bronchiseptica but the 
inhibition zone diameter of the combination of metaoxedrine with polymyxin B at 
the eye drop concentration was not significantly different from the inhibition zone 
diameter of the eye drop concentration of polymyxin B alone. Consequently, 
metaoxedrine was assumed to have no significant antibacterial activity against B. 
bronchiseptica at concentrations below 0.12 %w/v. 
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Thiomersal 
Thiomersal is different from both benzalkonium chloride and metaoxedrine (Table 
5.4). Thionlersal both alone and in combination with polymyxin B produced zones 
of inhibition against B. bronchiseptica in agar medium B. The significant 
difference of inhibition zone diameter of polymyxin B alone from polymyxin B plus 
thiomersal and the consistent increase in inhibition zone from low concentration to 
high concentration of thiomersal indicated that thiomersal inhibited the growth of B. 
bronchiseptica at a concentration as low as 0.00002 %. 
Gramicidin 
The other ingredient examined in this series of investigations was gramicidin. Since 
gramicidin is insoluble in water but freely soluble in alcohol, the solution of 
gramicidin was prepared in 20 %v/v ethanol. As shown in Table 5.5, this 
concentration of ethanol did not have any inhibitory effect on B. bronchiseptica. 
The results with gramicidin were not consistent although repeat determinations were 
made. However, the overall data suggested that gramicidin did not show 
significant growth inhibition against B. bronchiseptica. 
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Table 5.1 Effect of trimethoprim on the effect of polymyxin B against 
B. bronchiseptica 
Antimicrobial agent Inhibition zone diameter(mm) : mean(SD) , n = 8 
Eye Drop Diluted concentration 
concentration 
PMB(U/ml) (10,000)5 (160)4 (80)3 (40)2 
30.7(0.02) 19.3(0.04) 17.8(0.03) 16.5(0.03) 
TMP(%w/v) (0.1)10 (0.0016)9 (0.0008)8 (0.0004)7 
30.9(0.08) n n n 
(20)1 
15.5(0.00) 
(0.0002)6 
n 
PMB(U/ml) (10,000 +0.1)15 (160+0.0016)14 (80 +0.0008)13 (40+0.0004)12 (20+0.0002) 11 
+TMP(%wlv) 
t-test (p=0.05) 
PMB = polymyxin B 
TMP = trimethoprim 
31.9(0.09) 
5 and 15 
+ 
n = no inhibition zone 
+ = significant difference 
no-significant difference 
18.9(0.03) 
4 and 14 
-
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17.8(0.03) 16.5(0.03) 15.3(0.03) 
3 and 13 2 and 12 1 and 11 
- -
-
Table 5.2 Effect of neomycin on the effect of polymyxin B against 
B. bronchiseptica 
Antimicrobial Inhibition zone diameter(mm) : mean(SD), n = 8 
agent 
Eye drop Diluted concentration 
concentration 
PMB(U/ml) (16,250)5 (160)" (80)3 (40)2 
31.6(0.04) 19.8(0.03) 18.7(0.00) 17.4(0.02) 
N(%w/v) (0.5)10 (0.008)9 (0.004)8 (0.002)7 
21.4(0.08) n n n 
(20)1 
16.2(0.01 ) 
(0.001)6 
n 
PMB(U/ml) (16,250+0.5) 15 (160+0.008)14 (80+0.004)13 (40+0.002) 12 (20+0.001) 11 
+N(%w/v) 
t-test (p = 0.05) 
PMB = polymyxin B 
N = neomycin 
33.0(0.03) 
5 and 15 
+ 
n = no inhibition zone 
+ = significant difference 
= no-significant difference 
19.8(0.03) 
4 and 14 
-
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18.9(0.01 ) 17.3(0.00) 16.1 (0.03) 
3 and 13 2 and 12 1 and 11 
- - -
Table 5.3 Effect of benzalkoniumchloride and metaoxedrine on the effect of 
polymyxin B against B. bronchiseptica 
Antimicrobial agent Inhibition zone diameter of eye drop concentration(mm) 
(PMB 16,250 U/ml )5 
(BZK 0.004 %w/v )10 
(PMB 16,250 U/ml 
+ BZK 0.004 %w/v)15a 
t-test (p = 0.05) 
5 and 15a 
(PMB 16,250 U/ml )5 
(M 0.12% w/v) 1 0 
(PMB 16,250 U/ml 
+ M 0.12 %w/v)15b 
t-test (p = 0.05) 
5 and 15b 
PMB = polymyxin B 
BZK = benzalkonium chloride 
M = metaoxedrine 
+ = significant difference 
= no-significant difference 
mean(SD), n = 8 
31.8(0.05) 
8.0* 
32.0(0.07) 
-
36.7(0.09) 
10.4(0.03) 
36.7(0.05) 
-
* = the diameter of the well ie no observed inhibition 
Since eye drop concentration of polymyxin B plus benzalkonium chloride and 
polymyxin B plus metaoxedrine were not significantly different from eye drop 
concentration of polymyxin B alone, the effect of diluted concentration of 
benzalkonium chloride and metaoxedrine on the effect of polymyxin B against 
B. bronchiseptica was not investigated. 
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Table 5.4 Effect of thiomersal on the effect of polymyxin B against 
B. bronchiseptica 
Antimicrobia Inhibition zone diameter (mm) : mean(SD) , n = 8 
I agent 
Eye drop Diluted concentration 
concentration 
PMB(U/ml) (10,000)5 (160)4 (80)3 (40)2 
29.8(0.03) 19.7(0.06) 17.8(0.05) 15.4(0.04) 
TMS(%w/v) (0.005)10 (0.00008)9 (0.00004)8 (0.00002)7 
31.6(0.06) 16.1 (0.27) 12.5(0.09) 7.9(0.06) 
(20)1 
12.9(0.04) 
(0.00001)6 
n 
PMB(Ulml) (10,000+0.005) 15 (160+0.00008) 14 (80+0.00004) 13 (40+0.00002) 12 (20+0.00001) 11 
+TMS(%w/v) 
32.2(0.06) 
t-test ( p = 5 and 15 
0.05) 
+ 
PMB = polymyxin B 
TMS = thiomersal 
n = no inhibition zone 
+ = significant difference 
= no-significant difference 
22.6(0.08) 
4 and 14 
+ 
20.9(0.05) 18.8(0.02) 16.7(0.02) 
3 and 13 2 and 12 1 and 11 
+ + + 
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Table 5.5 Effect of gramicidin on the effect of polymyxin B against 
B. bronchiseptica 
Antimicrobial agent Inhibition zone diameter(mm) : mean(SD) , n = 8 
PMB(Ulml) (160) 1 (80)2 (40)3 (20)4 
21.7(0.02) 19.4(0.04) 16.1(0.02) 11.7(0.06) 
20.0(0.04) 18.3(0.02) 15.3(0.03) 12.1 (0.06) 
PMB(Ulml) (160)5 (80)6 (40)7 (20)8 
+20%v/v Ethanol 
21.4(0.02) 20.5(1.75) 16.4(0.04) 12.2(0.01) 
19.8(0.05) 17.5(0.04) 15.3(0.03) 12.7(0.05) 
G(%w/v) (0.00008)9 (0.00004) 10 (0.00002) 11 (0.00001) 12 
+20%v/v Ethanol 
14.2(0.01) 12.4(0.10) 9.3(0.01) n 
12.0(0.02) 9.3(0.00) 9.1(0.02) 8.1 (0.01) 
PMB(Ulml)+G(%w/v) (160+0.00008) 13 (80+0.00004)14 (40+0.00002)15 (20+0.00001) 16 
+20%vlv Ethanol 
21.1(0.05) 19.2(0.02) 17.2(0.02) 14.7(0.08) 
20.1 (0.03) 17.9(2.61) 13.5(0.03) 13.5(0.03) 
Ethanol (20%v/v)0 
n 
n 
1. PMB alone and PMB + 20 %v/v Ethanol 
1 and 5 2 and 6 3 and 7 4 and 8 
- - -
+ 
-
+ - + 
t-test ( p = 0.05 ) 2. PMB + 20 %v/v Ethanol and PMB + G + 20 %v/v Ethanol 
PMB = polymyxin B 
G = gramicidin 
n = no inhibition zone 
5 and 13 
-
-
1 and 13 
+ 
-
+ = significant difference 
= no-significant difference 
6 and 14 7 and 15 8 and 16 
- -
+ 
-
+ + 
3. PMB alone and PMB + G + 20 %v/v Ethanol 
2 and 14 3 and 15 4 and 16 
- -
+ 
+ + + 
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5.4 Conclusion 
The antibacterial activity of the additional chemicals present in commercial 
polymyxin B eye drop formulations was investigated. At the concentrations used in 
the microbiological assay of polymyxin B, none of these substances, except 
thiomersal, had any effect on the test organism (B. bronchiseptica). The 
microbiological assay of the polymyxin B for one of the eye drop formulations 
\vhich \vas to be used in the stability determinations was slightly modified from the 
agar plate diffusion method of the British Pharmacopoeia [44]. The BP method 
could be applied to the polymyxin B eye drops containing trimethoprim, neomycin, 
benzalkonium chloride, metaoxedrine and gramicidin at concentrations of 0.1 %w/v, 
0.5 %\\"/v, 0.004 %w/v, 0.12 %w/v and 0.0025 %w/v, respectively but not for the 
eye drops containing thiomersal. In order to assay the eye drops containing 0.005 
%w/v of thiomersal, thiomersal has to be added to the standard solution at the same 
concentration that it is present in the eye drops in order to avoid the enhanced effect 
on the test organism produced by the thiomersal. 
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Chapter 6 
Microbiological assay of polymyxin B solutions 
6.1 Introduction 
This chapter describes the microbiological assay of both undecomposed and 
decomposed polymyxin B solutions. The method used was the agar plate diffusion 
as suggested in the British Pharmacopoeia with addition of 0.005 % thiomersal in 
freshly prepared standard polymyxin B solution for sample that contained 
thiomersal. Barnard [15] has reported that an improved turbidimetric assay method 
has enabled a comparative study to be made of the antibiotic potencies of PB 1 and 
PB2 in the traditional agar plate diffusion assay and the nutrient broth turbidimetric 
assay. The PBl and PB2 fractions were shown to be of similar potency when 
assayed turbidimetrically while PB2 was more potent on agar plate diffusion assay 
than PB 1. These results from agar plate diffusion assay are consistent with those of 
Thomas et al [42]. Barnard suggested that any standard used to establish the 
potency of a batch of polymyxin B sulphate should be as similar as possible to the 
test material in the contents of PBI and PB2. This could be a problem when 
comparing the activity of partially decomposed polymyxin B formulations in which 
the ratio of PB I to PB2 was different. Therefore it is necessary to determine 
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\vhether such a microbiological assay procedure can be used to determine the 
antibacterial activity of polymyxin B solutions during a stability study. 
6.2 Methods 
Only two undecomposed eye drops were assayed. Sample 1 and Sample 4 
represented the formulations containing thiomersal and without thiomersal, 
respectively. For decomposed samples: sample 1, 2, 3, 4, 5, 6, and polymyxin B 
alone prepared in phosphate buffer at pH 6.0 (PMB) stored at 60°C for 500 h were 
assayed. (see Table 2.7 for details of sample 1 -6 ) 
Inoculum preparation and assay procedure were as described in 4.2.1 except that the 
preparations and the arrangement of standard and unknown solutions were as 
follo\\"s: 
Preparation of standard solutions 
Standard solution for sample 1 were prepared by making 10,000 Vlml polymyxin B 
and 0.005 % wlv thiomersal in phosphate buffer at pH 6.0 and then diluting to 
achieve the concentrations 80 (S3)' 40 (S2) and 20 (S}) Vlml polymyxin B. 
Standard solutions for the others samples were prepared by making 16,250 Vlml of 
polymyxin B and diluting to achieve the concentrations of 80 (S3)' 40 (S2) and 20 
(S}) Vlml polymyxin B. 
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Preparation of unknown solutions 
Eye drop samples were diluted with phosphate buffer at pH 6.0 to get the 
concentrations 80 (D3), 40 (D2) and 20 (D 1) D/ml polymyxin B. 
Assay procedure 
The assay was carried out by the same method as described in 4.2.1 but the 
arrangement of standard and unknown solutions were as follows: 
3X3 Latin Square 
Dishes Solutions 
1 VI SI V2 S2 V3 S3 
") SI V2 S2 V3 S3 VI 
-
3 V2 S2 V3 S3 VI SI 
4 S2 V3 S3 VI SI V2 
5 V3 S3 VI SI V2 S2 
6 S3 VI SI V2 S2 D3 
S = standard V = unknown 
Statistical analysis of the results and the calculation of potency were carried out 
according to the methods described in the European Pharmacopoeia [61] and Finney 
[64]. 
94 
6.3 Results and discussion 
The microbiological assay of polymyxin B in two undecomposed eye drops ( sample 
1 and sample 4 ) was carried out. The results are shown in Table 6.1 and 6.2. The 
assay \vas based on the parallel-line model in which the two log-dose response lines 
of the preparation being examined and of the standard preparation should be parallel. 
They should be rectilinear over the range of doses used in the calculation (20 to 80 
U/ml). These conditions should be verified by validity tests for a given probability. 
The validity tests used in these experiments was the F test [61,64] at the 95 % level 
of significance. The most important parameters are regression, parallelism and 
linearity. The assay is valid if 
1) the regression which indicates the slope of the log-dose response line is highly 
significant. 
2) the deviation from parallelism of the regression curves is non-significant. 
3) the deviation from linearity of the regression curves is non-significant. 
The validity of the assays of undecomposed sample 1 and sample 4 was determined 
as shown in Table 6.1 and 6.2. Figs. 6.1 and 6.2 show the parallel lines resulting 
from plotting log concentration against inhibition zone diameter of standard and 
samples. The estimated potency of polymyxin B in both samples was higher than 
the stated label potency especially sample 4. The estimated potency of sample 1 
was within the range of the USP limits for a similar preparation containing 
polymyxin and neomycin ( 90 to 125 % labelled amount) but the estimated potency 
of sample 4 was much higher than the standard. The proportion of individual 
components of polymyxin in sample 1 was the same as for the standard but for 
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sample 4 the proportion of PB 1 to PB2 was different from the standard, as evidenced 
from the chromatograms in Fig. 2.5 and Fig. 2.7. The high estimated potency of 
sample -+ may result from this difference in proportion of PB 1 to PB2 between the 
standard solution and the sample. It is also possible that the original potency of 
both of the two samples was much higher than the stated label amounts. 
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Table 6.1 Microbiological assay of undecomposed sample 1 
Inhibition zone diameter (mm) : mean(SD) 
S1 15.8 (0.03) 
16.9 (0.02) 
18.4 (0.01) 
15.9 (0.03) 
17.3 (0.02) 
18.6 (0.02) 
S2 
S3 
U1 
U2 
U3 
Analysis of variance 
Source Degree of freedom Sum of square Mean square 
Preparations 1 3.50189 x 10-3 3.50189 x 10-3 
Regression 1 0.283562 0.283562 
Parallelism 1 6.25104 x 10-6 6.25104 x 10-6 
linearity 2 6.14792 x 10-4 3.07396 x 10-4 
Doses 5 287685 
Error 18 8.51631 x 10-3 4.73128 x 10-4 
Total 23 0.296202 
Stated label potency 10,000 U/ml 
Estimated potency 11,340.90 U/ml (113.41 % labeled amount) 
Fiducial limits 10,290.70 -12,521.60 U/ml (102.91-125.22 % labeled amount) 
Table 6.2 Microbiological assay of undecomposed sample 4 
Source 
Preparations 
Regression 
Parallelism 
Linearity 
Doses 
Error 
Total 
Stated label potency 
Estimated potency 
Inhibition Zone Diameter (mm) : mean (SO) 
S1 16.5 (0.03) 
17.8 (0.03) 
19.0 (0.03) 
17.4 (0.03) 
18.6 (0.03) 
19.8 (0.03) 
S2 
S3 
U1 
U2 
U3 
Analysis of variance 
Degree of freedom Sum of square Mean square 
1 592 592 
1 3725.11 3725.11 
1 4.15955 x 10-2 4.159559 x 10-2 
2 7.72559 3.86276 
5 4324.87 
30 265.125 8.8375 
35 4590 
16,250 Ulml 
25,517.54 U/ml (157.03 % labeled amount) 
F ratio 
7.40157 
599.335 
1.32121 x 10-2 
0.64971 
F ratio 
66.9873 
421.512 
4.70670 x 10-3 
0.437091 
Fiducial limits 22,691.50 - 28,955.55 U/ml (139.64 - 178.19 % labeled amount) 
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The results from the microbiological assays of the decomposed samples are not 
sho\vn because the relative potency of all samples obtained from parallel line assays 
(3 doses level) were not reliable. There was a significant departure from 
parallelism between the log dose - response line of standard and test. This was also 
reported by Thomas et al [42] when the higher range of doses (160, 80 and 40 Vlml) 
\\"ere used. The relative potency of decomposed samples compared to freshly 
prepared standard varied from 1.14 to 140.73. Thus the relative potencies of all 
samples \\"ere recalculated using only two doses that gave parallel lines. This is 
according to the European Phamacopoeia that at least three different doses of the 
reference substance and three doses of the antibiotic to be examined should be used 
initially. If the relationship between the logarithm of concentration of the antibiotic 
and the diameter of the zone of inhibition has been shown to be linear for a given 
system. assays may be carried out using only two concentrations of the reference 
substance and two of the antibiotic to be examined [61]. However, the relative 
potency of all samples was still higher than the relative potency of the standard. It 
was concluded from these overall results that the microbiological assay was not 
suitable for monitoring the potency of polymyxin B in the stability study. 
Therefore killing time determinations for polymyxin B eye drops and the standard 
material against Pseudomonas aeruginosa NCTC 6750 were developed as a possible 
alternative. These are described and used in chapters 7-9. 
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Chapter 7 
Effect of inactivating recovery medium on polymyxin B 
activity 
7.1 Introduction 
Killing time determinations were investigated in order to attempt to use this method 
of assessment to differentiate between the microbiological activity of polymyxin B 
in different samples. The killing curves were obtained using a microdilution viable 
counting method. In this method the dilutions of antibacterial test samples 
combined with the test organism were made using medium containing suitable 
inacti\'ating agents for polymyxin B and any other ingredients that may affect the 
test bacteria. The numbers of bacteria remaining at specified time was calculated 
from these dilutions. 
The first objective of this section was to find a suitable inactivating recovery 
medium for using in the killing time determinations for polymyxin B in phosphate 
buffer pH 6.0. The second objective was to select an appropriate concentration of 
polymyxin B for use in the first row of wells in the microtiter plate. 
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The effects of two inactivating agents for polymyxin B ( lecithin and magnesium 
sulphate) using P. aeruginosa NCTC 6750 as the test organism were investigated. 
Lecithin at a concentration of 0.125 %w/v has been used to inactivate cationic 
antibacterials agents in lozenges and also solutions of polymyxin B [17,62,65]. In 
this study, a lower concentration of lecithin (0.025 %w/v) was used. Polysorbate 80 
cannot be used to help solubilize the lecithin in this study because polysorbate 80 is 
synergistic \yith polymyxin against P. aeruginosa. The surface active agent causes 
the polymyxin damaged cells to lyse. However, without the polysorbate 80 it is 
difficult to get the lecithin into solution. 
Seyeral workers have noted that the effect of polymyxin - e.g. binding to membrane 
and lipids, changes in membrane permeability, inhibition of growth - can be 
antagonized by divalent cations and the presence of Mg2+ and Ca2+ has been 
reported to inhibit antibacterial activity of polymyxin B [14,66-68]. It is also 
known that Mg2+ and Ca2+ have an important role in stabilizing the outer membrane 
of Gram-negative bacteria [14]. In this work it was decided to investigate two 
concentrations of magnesium sulphate (0.5% and 1 %w/v) and to compare the results 
with lecithin. The effectiveness of the selected inactivating agent was tested when 
it was incorporated in water, nutrient broth and thioglycollate broth. 
The killing time determinations of different concentrations of polymyxin B prepared 
in water and phosphate buffer pH 6.0 using an appropriate inactivating recovery 
medium were also investigated. 
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7.2 Methods 
P. aeruginosa NCTC 6750 was used as the test organism. Inoculum preparation for 
all experiments in this chapter was as described in 4.2.2.1. 
7.2.1 Calibration curve 
The cell suspension from 4.2.2.1 was diluted with normal saline solution to give five 
suspensions haying absorbance readings in the range 0.05 to 0.25 at a wavelength of 
500 run. Dilutions for viable counting were made by further diluting each of the 
cell suspensions to produce a cell concentration of approximately 102 CFU/ml. 
Dilutions of each absorbance reading were made to produce approximately 107, 106, 
10). 10-+~ 103 and 102 CFU/ml and were pipetted in 0.1 ml volumes onto the surface 
of oyerdried nutrient agar plates and spread evenly with sterile angled glass rods. 
This procedure was carried out in triplicate and after incubation at 32°C for 15 h, the 
number of colony forming units ( CFU ) per 0.1 ml were counted and recorded. The 
dilution giving a countable number of CFU's (50-200) was counted and the CFU of 
the original culture calculated. The calibration curve was plotted for log viable 
count per ml ( log CFU/ml ) versus absorbance readings. 
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7.2.2 Effect of lecithin and magnesium sulphate 
Three types of test sample containing lecithin and magnesIum sulphate were 
prepared as shown in Table 7.l. The final concentrations of lecithin, magnesium 
sulphate and polymyxin B were 0.025 %w/v, 1.0 %w/v and 1000 Vlml, respectively. 
The concentration of 1000 Vlml was used for all test samples. When these samples 
\yere diluted in microtiter plates, the concentration of polymyxin B in row 1, in 
\yhich it was inactivated was about 400 Vlml. The original concentration of 
polymyxin B may be 25 % higher than stated on the label and for this reason it was 
not possible to know the exact concentration of polymyxin B in the diluted eye 
drops. That is the concentration in row 1 could be as high as 500 Vlml. Therefore 
the concentration of 1000 Vim I was considered to be high enough to test the 
effectiveness of the inactivating recovery medium. For every test sample, the 
bacterial suspension was the last addition to be made to the first row of wells. At 
the contact times of 2 and 12 min, 0.1 ml of each sample was withdrawn and 
suitably diluted for the viable count. The subsequent procedure was as described in 
7.2.l. 
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Table 7.1 Components of the test samples used for testing the effect of 
magnesium sulphate and lecithin on the effect of polymyxin B on the viability of cell 
suspensions of P. aeruginosa NCTC 6750 
Bacteria Magnesium Polymyxin 
suspension sulphate* and solution 
:absorbance lecithin** 10,000 No. 
0.175 - 0.185 (ml) 
U/ml 
(ml) (ml) 
1. Bacteria + 0.05 4.5 -
Inactivator 
2. Bacteria + 0.05 - 0.5 
PMB 
3. Bacteria + 0.05 4.5 0.5 
Inactivator + 
PMB 
* = Magnesium sulphate 1 g in 89 ml nutrient broth 
** = Lecithin 0.025 g in 89 ml nutrient broth 
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B 
Water Nutrient broth 
(ml) (ml) 
0.5 -
- 4.5 
- -
7.2.3 Effect of magnesium sulphate 0.5 and 1 % w/v 
The objectiye of this section was to determine whether magnesium sulphate 1 %w/v 
is a suitable concentration for using to inhibit polymyxin B at the concenrations 
used. T\yo types of test samples containing magnesium sulphate were prepared as 
shown in Table 7.2. The final concentration of polymyxin B was 1000 U/ml. For 
eyery test sample. the bacterial suspension was added last in order. At the contact 
times of 2. 12 and 22 min, 0.1 ml of each sample was withdrawn and diluted for 
viable counting using the procedure described in 7.2.1. 
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Table 7.2 Components of the test samples used for testing the effect of different 
concentrations of magnesium sulphate on the effect of polymyxin B on the viability 
of cell suspensions of P. aeruginosa NCTC 6750 
Bacteria 
suspension: 
Magnesium Polymyxin B Water 
absorbance 
sulphate· solution No. (ml) 
0.175-0.185 
(ml) :10,000 U/ml 
(ml) (ml) 
1. Bacteria + 0.05 4.5 - 0.5 
MgS04 
2. Bacteria + 0.05 - 0.5 -
PMB 
3. Bacteria + 0.05 4.5 0.5 -
MgS04 
4. Control 0.05 - - 0.5 
* 0.5 g in 89 ml nutrient broth to make final concentraion to 0.5 % 
or 1.0 g in 89 ml nutrient broth to make final concentraion to 1.0 % 
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Nutrient broth 
(ml) 
-
4.5 
-
4.5 
7.2.4 Killing curves for different concentrations of polymyxin Busing 
magnesium sulphate 1 %w/v solution as an inactivating recovery medium 
Different concentrations of standard polymyxin B solutions ranging from 125 D/ml 
to 5000 D/ml were made in phosphate buffer as described in 4.2.2.2. Test solutions 
(150 J.lI) were mixed with 150 J.lI of cell suspension in row N of the microtiter 
plates. The wells in rows 1-6 were primed with magnesium sulphate 1 %w/v 
solution. Killing time detenninations of polymyxin B at concentrations of 2500, 
2000. 1000. 500. 250. 125 and 62.5 D/ml were then carried out following the 
methods described in 4.2.2.2. 
7.2.5 Killing curves for different concentrations of polymyxin B when 
prepared in water and phosphate buffer pH 6.0 
Phosphate buffer pH 6.0 was used in this study as a solvent for polymyxin B as 
recommended by the British Phamacopoeia [43]. This pH was found to be suitable 
for polymyxin B solution [55,56]. The objective of this section was to test whether 
there was any difference between the antibacterial activity of polymyxin B prepared 
in water and in phosphate buffer pH 6.0. The preparation of standard solutions of 
polymyxin B ranged from 125 D/ml to 5000 Dim I and the killing time 
detenninations were as described in 4.2.2.2. The inactivating recovery medium was 
magnesium sulphate 1 %w/v solution. 
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7.2.6 Effect of magnesium sulphate 1 %w/v when prepared in water, nutrient 
broth and thioglycollate broth 
Thioglycollate broth containing magnesIum sulphate 1 % wlv was prepared as 
described in 4.1.2.4. Thioglycollate broth was expected to be suitable for 
determining the killing times of polymyxin B in sample 1 which contains 
thiomersal. It would also have to be suitable for polymyxin B in the other samples. 
In order to compare the effectiveness of magnesium sulphate 1 %w/v when prepared 
in \\"ater. nutrient broth and thioglycollate broth, the three different solutions were 
prepared and added to rows 1-6 of the microtiter plates. In the previous section the 
results had shown that the most suitable concentration of polymyxin B was 2000 
U/ml. Therefore, standard polymyxin B 4000 U/ml was prepared in phosphate 
buffer. This was diluted to 2000 U/ml in the first row of wells in the microtiter 
plate and used as the test sample. Preparation of polymyxin B 4000 U/ml and 
killing time determinations were carried out as described in 4.2.2.2. 
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7.3 Results and discussion 
7.3.1 Calibration curve 
Fig. 7.1 shows good correlation between absorbance readings and log viable counts 
for P. aeruginosa NCTC 6 750. The concentration of bacteria used in the killing 
time detenninations should be approximately 108 to 109 CFU/ml. Therefore 
bacterial suspensions in the range of absorbance between 0.175 to 0.185 should be 
used for the subsequent experiments. 
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Fig. 7.1 Calibration curve of log CFU per milliliter against corresponding 
absorbance readings at 500 nm for cell suspensions of P. aeruginosa NCTC 6750. 
108 
7.3.2. Effect of lecithin and magnesium sulphate 
Tables 7.3. 7.4 and Figs. 7.2. 7.3 give the CFU/ml of P.aeruginosa at 2 min and 12 
min in three different types of sample. The differences between the numbers of 
bacteria at 2 and 12 min were analysed by the Student t-test (p=0.05). Lecithin 
0.025 %w/v had some inhibitory activity on the activity of polymyxin compared 
\\ith the activity of polymyxin in buffer and this is seen at 2 and 12 min. Although 
the number of bacteria in the lecithin 0.025 %w/v did show a slight decrease 
bem'een the 2 min and 12 min sample, this was considered to be the result of 
experimental error and not a killing effect of the lecithin on the P. aeruginosa cells. 
The t-test of bacterial numbers at 2 and 12 min in the presence of magnesium 
sulphate 1 % \v/v showed no significant difference. Although polymyxin B in the 
presence of magnesium sulphate 1 %w/v had a slight effect on the number of 
bacteria, the overall data showed that magnesium sulphate 1 %w/v was much more 
effectiye than lecithin 0.025 %w/v as an inactivator of polymyxin B 1000 U/m!' 
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Table 7.3 Effect of lecithin 0.025 %w/von the effect of polymyxin B 1000 U/ml 
on the viability of cell suspensions of P. aeruginosa NCTC 6750 
Sample 
1.Bacteria + Lecithin 
2. Bacteria + PMB 
3. Bacteria + PMB + 
Lecithin 
- = non - significant 
o = t-test was not performed 
+ = significant 
* = less than 103 CFU/ml 
2 min 
1.75 (0.12) 
0.57 (0.05) 
1.45 ( 0.14 ) 
CFU/ml: mean x 106 (SO X 106 ) J n=3 
t-test between 2 
and 12 min 
12 min 
(p = 0.05) 
1.44 (0.19) + 
* 0 
0.0165 ( 0.07 ) + 
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min 
Table 7.4 Effect of magnesium sulphate 1 %w/v on the effect of polymyxin B 1000 
U/ml on the viability of cell suspensions of P.aeruginosa NCTC 6750 
CFU/ml : mean x 106 (SO x 106). n=3 
t-test between 2 min 
Sample 2min 12 min 
and 12 min 
(p=O.05) 
1. Bacteria + MgS04 2.10 ( 0.38 ) 1.77 (0.10) 
-
2. Bacteria + PMB 5.70 (0.05) * 0 
3. Bacteria + PMB + 1.41 (0.16) 0.90 (0.00) + 
MgS04 
- = non - significant 
o = t-test was not performed 
+ = significant 
* = less than 103 CFU/ml 
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Fig. 7.2 Effect of lecithin 0.025 %w/v on the effect of polymyxin B 1000 U/ml on 
the viability of cell suspensions of P.aeruginosa NCTC 6750. 
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Fig. 7.3 Effect of magnesium sulphate 1 %w/v on the effect of polymyxin B 1000 
U/ml on the viability of cell suspensions of P.aeruginosa NCTC 6750. 
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7.3.3 Effect of magnesium sulphate 0.5 and 1.0 %w/v 
Tables 7.5.7.6 and Figs. 7.4. 7.5 show the number ofCFUs of P. aeruginosa at 0, 2, 
12 and 22 min in three different types of samples, i.e, either magnesium sulphate 0.5 
0/0 or 1.0 %\y!v. polymyxin 1000 U/ml and combinations of the two magnesium 
sulphate solutions \vith polymyxin. Similar results were obtained with both 
samples of polymyxin alone ( sample No.2). An analysis of variance (AN OVA ; p 
= 0.05) comparing the samples containing bacteria plus magnesium sulphate (sample 
No.1) and bacteria plus magnesium sulphate and polymyxin B (sample No.3) 
indicate that only samples contain magnesium sulphate 1.0 %w/v showed no 
significant reduction in the number of bacteria. This was slightly different from the 
results shown in Fig. 7.3 but in this test the inoculum was 100 times larger and the 
reduction in numbers shown in 7.3 would have a very small effect on the results 
given in 7.5. Magnesium sulphate 1 %w/v was chosen as a suitable concentration 
for inhibiting polymyxin B at concentrations around 1000 U/ml. Counts on 
bacterial suspensions in magnesium sulphate 0.5 %w/v did increase slightly ( Fig. 
7.4 ) but this was not taken to be of marked practical significance even though it was 
significantly different by the ANOV A. 
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Table 7.5 Effect of magnesium sulphate 0.5 %w/v on the effect of polymyxin 8 
1 000 U/ml on the viability of cell suspensions of P. aeruginosa NCTC 6750 
CFU/ml : mean x108 (SD X 108) , n=3 
No. o min 2 min 12 min 22 min ANOVA (p=0.05) 
1. Bacteria 1.04 1.04 1.38 1.25 
+0.5% ( 0.17) (0.14) (0.15) (0.22) + MgS04 
2. Bacteria 1.04 * * * 0 
+ PMB ( 0.17) 
3. Bacteria 1.04 0.62 0.64 0.39 
+ PMB + ( 0.17) (0.12) ( 0.12) (0.12) + 
0.5% 
MgS04 
Table 7.6 Effect of magnesium sulphate 1.0 %w/v on the effect of polymyxin 8 
1 000 U/ml on the viability of cell suspensions of P. aeruginosa NCTC 6750 
No. o min 
1. Bacteria 1.04 
:t 1.0% ( 0.17) 
MgS04 
2. Bacteria 1.04 
+ PMB ( 0.17) 
3. Bacteria 1.04 
+ PMB + ( 0.17) 
1.0% 
MgS04 
- = non - significant 
o = ANOVA was not performed 
+ = significant 
* = less than 103 CFU/ml 
CFU/ml : mean x1 08 (SO X 108) , n =3 
2 min 12 min 22 min 
1.17 1.13 1.36 
(0.07) (0.17) (0.35) 
* * * 
0.94 0.84 0.82 
(0.07) (0.17) (0.35) 
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ANOVA (p=0.05) 
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Fig . 7.4 Effect of magnesium sulphate 0.5 %w/v on the effect of polymyxin B 1000 
U/ml on the viability of cell suspensions of P. aeruginosa NCTC 6750. 
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Fig. 7.5 Effect of magnesium sulphate 1 %w/v on the effect of polymyxin B 1000 
U/ml on the viability of cell suspensions of P. aeruginosa NCTC 6750. 
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7.3.4 Killing curves of different concentrations of polymyxin Busing 
magnesium sulphate 1 %w/v as an inactivator 
The reduction in viable counts of the test organism with time produced by polymyxin 
B solutions prepared in phosphate buffer pH 6.0 are shown in Fig. 7.6. It appears 
that at the range of concentrations between 62.5 to 250 U/ml, the polymyxin B 
activity against P. aeruginosa was not very marked. The effect of these 
concentrations was similar to the control (water). Concentrations from 500 to 2500 
U/ml produced a greater reduction in the colony count. The greatest reduction in 
colony count was ~ 5 log cycle over 60 min. The concentration of 2000 U/ml was 
chosen for comparing the killing time of various polymyxin B samples. 
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Fig. 7.6 The reduction in CFU per milliliter of cell suspensions of P. aeruginosa 
NCTC 6750 produced by polymyxin B (U/ml) at graded concentrations. 
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7.3.5 Killing curves of graded concentrations of polymyxin B when prepared 
in ,Yater and phosphate buffer pH 6.0 
The killing curves of graded concentrations of polymyxin B ranging from 62.5 to 
2000 U/ml in water and phosphate buffer pH 6.0 are shown in Fig. 7.7 and 7.6. 
Analysis of variance (ANOV A, p=0.05) of all contact times and log CFU/ml showed 
significant differences between polymyxin B prepared in water and buffer at the 
concentrations of 500. 250. 125 and 62.5 U/ml. Tukey's Wholly Significance 
difference (WSD) was used to investigate this further. Both figures show that the 
differences in antibacterial activity of polymyxin B prepared in water and buffer 
started to become obvious after the contact time of 50 min. In Fig. 7.6, the number 
of bacteria at 50 min was not determined. Therefore, the contact time of 60 min 
\vas chosen to test for differences. The number of bacteria after 60 min contact with 
polymyxin B 2000 and 1000 U/ml in water were less than the detection limit (103 
CFU/ml). Log 103 (3) was used for the statistical analysis to compare with the 
effect of the polymyxin in the buffer. At 60 min, ANOV A (p=0.05) of log CFUlml 
of all samples showed that there were significant differences in the number of 
bacteria killed by different samples. The WSD was used to test which sample was 
most likely to be responsible for this result. The test reduces the possibility of false 
positives compared with pairwise 't' tests [70]. The results indicate that the number 
of bacteria after 60 min contact with polymyxin B 2000, 1000 Ulml in water were 
lower than those in contact with other samples. From this it appears that polymyxin 
B may have more activity when prepared in water. Polymyxin B 2000 and 1000 
U/ml prepared in water reduced the number of bacteria from about 109 to about 103 
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CFU/ml after 50 min while the number of bacteria in the polymyxin B solutions 
prepared in buffer remained at concentration greater than 105 CFU/ml at 60 min. 
Phosphate ion in the buffer may affect the activity of polymyxin B against P. 
aeruginosa. Polymyxin B is able to mimic 'head and tail' features of phospholipids 
and this allows polymyxin B to become incorporated within the membrane. The 
heptapeptide core serves as a polar head to complement the polar glycerol-derived 
phosphate moiety of the phospholipid unit. The fatty acid tail which extends from 
the cyclic core serves as a hydrophobic tail similar to that of the unsaturated and 
saturated long chain aliphatic fatty acids which comprise the tail of the 
phospholipids [16]. The presence of high concentrations of phosphate ion may 
preyent the binding of the polar head of polymyxin B to the phospholipid and 
therefore reduce the activity of polymyxin B. However, it is proposed to use 
phosphate buffer pH 6.0 as a solvent for polymyxin B in all experiments in this 
study. This is in order to ensure that the pH remains constant at the high 
temperatures used in the stability studies of polymyxin B solutions. The buffer 
should counteract any changes of pH which might be produced by the release of 
alkaline substances from the glass containers. Thus the use of phosphate buffer pH 
at 6.0 as a solvent for polymyxin was considered necessary. 
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Fig . 7.7 Killing curves of graded concentrations of polymyxin B (U/ml) prepared in 
water 0N) against cell suspensions of P. aeruginosa NCTC 6750. 
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7.3.6 Effect of magnesium sulphate 1 %w/v when prepared in water, nutrient 
broth and thioglycollate broth 
Killing curves produced by polymyxin B 2000 U/ml dissolved in aqueous 
magnesium suphate and in magnesium suphate dissolved in 2 different media are 
shown in Fig. 7.9. The difference in activity of polymyxin B 2000 U/ml when 
dissolved in 2 media was tested for significance using ANOVA (p=0.05) for all 
contact times and log CFU/ml. The results show that there was no significant 
difference between the activity of polymyxin B 2000 U/ml when dissolved in 
magnesium sulphate 1 %w/v aqueous solution, magnesium sulphate 1 %w/v nutrient 
broth and magnesium sulphate 1 %w/v thioglycollate broth ( Fig. 7.8). This also 
indicates that the inactivating effectiveness of magnesium sulphate 1 %w/v was not 
affected by the substances present in nutrient broth or thioglycollate broth. 
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7.4 Conclusions 
The effect of different types of inactivating recovery solutions on polymyxin B 
activity was investigated. Magnesium sulphate (1 %w/v) was found to be more 
suitable than lecithin (0.025 %w/v) for inactivating polymyxin B activity against 
P.aeruginosa NCTC 6750 at a concentration of 1000 U/ml. This concentration of 
magnesium sulphate can be used in aqueous solution, nutrient broth or thioglycollate 
broth without significant differences in the effect of polymyxin B on the killing 
curve. The most suitable concentration of polymyxin B for use in the first row of 
\vells in the microtiter plate was 2000 U/ml. There were significant differences 
between polymyxin B prepared in water and buffer at the concentrations of 500, 250, 
125 and 62.5 U/ml. Polymyxin B prepared in water at concentrations of 2000 and 
1000 U/ml were shown to be more active against the test organism after 60 min 
contact than solutions prepared in phosphate buffer pH 6.0. 
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Chapter 8 
Effect of preservatives and second antibacterials present in 
eye drops on polymyxin B bactericidal activity against 
P. aeruginosa NCTC 6750 
8.1 Introduction 
The effects of preservatives and second antibacterials present in eye drops on 
polymyxin B activity against B. bronchiseptica NCTC 8344 were investigated in 
chapter 5. This organism was chosen as a test bacteria as suggested in the British 
Pharmacopoeia for the microbiological assay of polymyxin B. However, the 
results in chapter 6 indicate that the microbiological assay was not suitable for 
monitoring the potency of polymyxin B in the stability study. Therefore, killing 
time determinations for polymyxin B against P. aeruginosa NCTC 6750 were 
investigated as the test system. P. aeruginosa NCTC 6750 was used as the test 
organism since the bactericidal activity of polymyxin B against this organism has 
been reported frequently [9,11,17,65,66]. 
The objective of this chapter was to determine whether or not the preservatives and 
second antibacterials present in polymyxin B eye drops had effects on polymyxin B 
activity against P. aeruginosa NCTC 6750. Previous results ( chapter 7 ) indicated 
123 
that magnesium sulphate 1 %w/v was suitable for inactivating polymyxin B activity 
and it could be used effectively at this concentration in aqueous solution, nutrient 
broth or thioglycollate broth. In this chapter, thioglycollate broth containing p_ 
aminobenzoic acid (PABA) 0.16 %w/v and magnesium sulphate 1 %w/v was used 
as an inactivating recovery medium. Thioglycollate broth and PABA were expected 
to inhibit the activity of thiomersal and trimethoprim present in sample 1 (Table 
8.1). This concentration of PABA was used following Richards el al findings that 
12.5 j.lg ofTMP could be inhibited by 50 Jlg of PABA [71]. PABA has been found 
to enhance the activity of other antibacterials due to its ability to increase the 
bacterial cell envelope permeability[17,65,66]. Richards and Xing [17] reported 
that subinhibitory concentrations of polymyxin B and PABA had synergistic 
inhibitory activity against P. aeruginosa. The killing time determinations were 
carried out at 37°C over a period of 5 h. The conditions were different from this 
current study in which test samples were maintained at room temperature for 1 h. 
Under these conditions PABA was not expected to have an effect on the activity of 
polymyxin B since this was not a suitable environment for cell growth and PABA 
can only affect the cell envelope permeability of dividing cells [65]. 
Test substances included thiomersal (TMS), trimethoprim (TMP), neomycin (N) and 
gentamicin (G). Thiomersal and trimethoprim were used as the preservative and the 
second antibacterial in sample 1. Neomycin (sample 2, 3, 4, 5 and 6) and 
trimethoprim (sample 1) had been included in the eye drops in order to extend the 
spectrum of activity of the formulations. Gentamicin was not included in any of the 
test samples but its activity was tested in this investigation because it is, like 
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neomycin, an amino glycoside. The concentrations investigated were the 
concentrations of gentamicin included in eye drops of the British National 
Formulary [72]. 
The specific effect of other ingredients present in some of the test samples 
l benzalkonium chloride, gramicidin and metaoxedrine ) were not tested. 
Benzalkonium chloride, as a quaternary ammonium compound, is active against 
Gram-positive bacteria and less active against Gram-negative organisms, especially 
P. aeruginosa [73]. It is used as a preservative for samples 3, 4, 5 and 6. High 
concentrations of benzalkonium chloride ( 0.1 %w/v ) have been used as a 
disinfectant for P. aeruginosa [74,75]. However, P. aeruginosa is often highly 
resistant to quaternary ammonium compounds (QACs). A factor of considerable 
importance for bacterial resistance is the cation content of the bacterial outer cell 
membrane. The Mg2+ content having the greatest influence in P. aeruginosa cells 
[16]. Mg2+ was added to the recovery medium for determining the killing times of 
polymyxin B samples. In addition, the concentration of benzalkonium chloride in 
the test samples was diluted as low as 0.001 or 0.002 %w/v. Both the low 
concentrations of benzalkonium chloride and the high concentrations of Mg2+ would 
effectively inactivate the activity of benzalkonium chloride on P. aeruginosa. 
Gramicidin was present in sample 2 in order to extend the spectrum of activity 
against Gram-positive bacteria. It is primarily active against many species of 
Gram-positive bacteria but many of the Gram-negative bacterial species are 
unaffected by gramicidin. This is due to the outer layer of the bacterial cell envelope 
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preyenting the compound gaining access to and exerting its action on the bacterial 
cytoplasmic membrane[9J 1,16]. 
Metaoxedrine or phenylephrine hydrochloride was present in sample 6 at 
concentration of 0.12 %w/v. It is employed in eye drops as a mydriatic in 
concentrations of up to 1 0 %w/v [9]. There is no reported activity of this substance 
against P. aeruginosa. Consequently, it was not expected that metaoxedine would 
haye an effect on the activity of polymyxin B against P. aeruginosa. 
8.2 Methods 
P. aeruginosa NCTC 6750 was used as the test organism. Inoculum preparation for 
all experiments in this chapter were as described in 4.2.2.1. 
The test solutions ( 150 j..ll ) were mixed with 150 j..ll of cell suspensions in the first 
row of wells in the microtiter plates. The wells in rows 1 to 6 of the microtiter 
plates were primed with 200 j..ll of thioglycollate broth containing PABA 0.16 %w/v 
and magnesium sulphate 1 %w/v. Killing time determinations were carried out as 
described in 4.2.2.2. 
The solutions of polymyxin B in combination with other substances at the 
concentrations contained in the eye drops were diluted to give 4000 D/ml of 
polymyxin B ( see Table 8.1 ) and tested by the same procedure as that used for 
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polymyxin B alone. The concentrations given in the last column of Table 8.1 were 
diluted by a factor of 2 in the first row of wells in the microtiter plates. Phosphate 
buffer pH 6.0 was used as the control. The preparations of polymyxin B In 
combination with the other substances are given in Table 8.1. 
Table 8.1 Ingredients of the test eye drops 
Sample Ingredients 
1 (Wel/come*) PMB 10,000 U/ml 
TMP 0.1 %w/v 
(Preservative TMS 0.005 a/ow/v) 
2 ( Seng Thai *) PMB 5000 U/ml 
NO.2 %w/v 
Gramicidin 0.025 %w/v 
** 
3 ( Dispersa*) PMB 15,000 U/ml 
N 0.35 %w/v 
(Preservative BZK 0.01 %w/v) 
4 (ALcon*) PMB 16,250 U/ml 
N 0.35 %w/v 
(Preservative BZK 0.004 %w/v) 
5 (Alcon*) PMB 16,250 U/ml 
N 0.35 %w/v 
(Preservative BZK 0.004 %w/v) 
6 (Alcon*) PMB 16,250 U/ml 
N 0.35 %w/v 
Metaoxedrine or Phenylephrine 
hydrochloride 0.12%w/v 
(Preservative BZK 0.004%w/v) 
PMB = polymyxin B, TMP = trimethoprim, 
TMS = thiomersal, N= neomycin, BZK = benzalkonium chloride 
* Manufacturer 
** Preservative is not stated 
Sample 1,4 and 6 were obtained from U.K. 
Sample 2, 3 and 5 were obtained from Thailand 
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Concentration when 
polymyxin B is diluted to 
4000 U/ml 
0.04 %w/v 
0.002 %w/v 
0.16 %w/v 
0.02 %w/v 
0.08 %w/v 
0.002 %w/v 
0.08 %w/v 
0.0010 %w/v 
0.08 %w/v 
0.0010 %w/v 
0.08 %w/v 
0.030 %w/v 
0.0010 %w/v 
8.2.1 Effect of thiomersal and trimethoprim 
Test solutions were prepared as shown in Table 8.2. 
Table 8.2 Components of the test samples used for testing the effect of thiomersal 
(TMS) and trimethoprim (TMP) on the effect of polymyxin B (PMB) on the viability 
of cell suspensions of P. aeruginosa NCTC 6750 
Sample PMB* TMS* TMP* Phosphate 
(ml) (ml) (ml) buffer pH 6.0 
to 
(ml) 
1. PMB 4 - - 10 
4000 U/ml 
2. TMS - 1 - 10 
0.002 %w/v 
3. PMB 4 1 - 10 
4000 U/ml 
+TMS 
0.002 %w/v 
4. PMB 4 - 1 10 
4000U/ml 
+TMP 
0.04 %w/v 
5. PMB 4 1 1 10 
4000 U/ml 
+TMS 
0.002 %w/v 
+TMP 
0.04 %w/v 
6. TMS - 1 1 10 
0.002 %w/v 
+TMP 
0.04 %w/v 
7. TMP 0.04 - - 1 10 
%w/v 
PMB* = 0.0329 9 of polymyxin B sulphate ( 7690 U/mg ) in 25 ml of phosphate 
buffer pH 6.0 (10,000 U/ml) 
TMS* = 0.02 9 of thiomersal in 100 ml of phosphate buffer pH 6.0 (0.02 %w/v) 
TMP* = 0.1 9 of trimethoprim in 25 ml of phosphate buffer pH 6.0 (0.4 %w/v) 
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8.2.2 Effect of neomycin 
8.2.2.1 Killing time determinations 
Test solutions were prepared as shown in Table 8.3. 
Table 8.3 Components of the test samples used for testing the effect of neomycin 
(N) on the effect of polymyxin B (PMB) on the viability of cell suspensions of P. 
aeruginosa NCTC 6750 
Sample PMB* N* Phosphate buffer 
(ml) (ml) pH 6.0 to 
(ml) 
1. N 0.32 %w/v - 5 10 
2. N 0.16 %w/v - 2.5 10 
3. N 0.08 O/oW/V - 1.25 10 
4. N 0.0384 %w/v - 0.6 10 
5. PMB 4000 U/ml 4 - 10 
6. PMB 4000 U/ml 4 5 10 
+ N 0.32 %w/v 
7. PMB 4000 U/ml 4 2.5 10 
+ N 0.16 %w/v 
8. PMB 4000 U/ml 4 1.25 10 
+ N 0.08 %w/v 
9. PMB 4000 U/ml 4 0.6 10 
+ N 0.0384 %w/v 
PMB* = 0.0329 9 of polymyxin B sulphate ( 7690 U/mg ) In 25 ml of phosphate buffer pH 6.0 (10,000 
U/ml) 0 
N* = 0.4706 9 of neomycin sulphate (680 Ilg/mg) in 50 ml of phosphate buffer pH 6.0. (0.64 Yow/v) 
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8.2.2.2 Possible chemical interaction between polymyxin B and neomycin 
Killing time determinations showed that neomycin alone at the concentrations tested 
\YUs not actiYe against P. aeruginosa but the combination of all concentrations of 
neomycin with polymyxin B 2000 D/ml seemed to produce a slower reduction in the 
viable counts of the test organism with time than polymyxin B alone. Therefore 
tests \yere carried out to determine whether there was a chemical interaction between 
these t\\"o substances which could reduce the amount of available polymyxin B. 
Initial measurements were carried out by determining absorbances at 2 wavelengths, 
200 and 220 nm. The test solutions were prepared as follows: 
The calibration curves for polymyxin B concentrations ranged from 10 to 250 D/ml 
(200 nm ) and 50 to 250 D/ml (220 nm) were plotted from the absorbances of 
polymyxin B solutions against concentrations. The preparation of polymyxin B at 
these concentration were described in Table 8.4. 
The test solutions used for testing the chemical interaction between polymyxin B 
and neomycin were prepared as indicated in Table 8.3. The solutions were diluted 
2-times with phosphate buffer pH 6.0 and then 10-times with the same solvent to 
give suitable concentrations for determining the absorbance readings at 200 nm. The 
absorbance readings were carried out in triplicate. The same procedure was also 
carried out at a wavelength of 220 nm except that at this wavelength the test 
solutions were only diluted 2-times. 
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Table 8.4 Components of polymyxin B solutions used in calibration curves at the 
wavelength of 220 nm 
Polymyxin B PMB* (ml) Phosphate buffer pH 6.0 
concentration (U/ml) to (ml) 
100 0.1 10 
200 0.2 10 
500 0.5 10 
1000 1.0 10 
1500 1.5 10 
2000 2.0 10 
2500 2.5 10 
PMB* = 0.0329 g of polymyxin B sulphate ( 7690 U/mg ) in 25 ml of phosphate 
buffer pH 6.0 (10,000 U/ml) 
All solutions were diluted ten-times with buffer to achieve the concentrations of 10, 
20, 50, 100, 150, 200 and 250 D/ml for determining the absorbance measurements at 
200 nm. 
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The above results were confirmed by obtaining complete spectrum at the range 200 _ 
300 nm. 
The test solutions were prepared as shown in Table 8.5. 
Table 8.5 Components of the test samples used for the absorbance scanning 
from 200 to 300 nm 
Sample PMB* (ml) N* (ml) Phosphate buffer 
pH 6.0 to (ml) 
1. PMB 2000 U/ml 2.5 - 12.5 
2. PMB 2000 U/ml 2.5 1.6 12.5 
+ N 0.08 %w/v 
3. PMB 2000 U/ml 2.5 3.2 12.5 
+ N 0.16 %w/v 
PMB* = 0.0329 9 of polymyxin B sulphate ( 7690 U/mg ) in 25 ml of phosphate 
buffer pH 6.0 (10,000 U/ml) 
N* = 0.4706 9 of neomycin sulphate (680 Jlg/mg) in 50 ml of phosphate buffer pH 
6.0. (0.64 0/0) 
The absorbances of the test samples were scanned at the wavelength of 200 to 300 
nm using a UV -Visible Recording Spectrophotometer Type UV -160A ( Shimadzu ). 
The spectrum of sample No.1 was superimposed with sample No.2 and 3. 
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8.2.3 Effect of gentamicin 
Test solutions were prepared as described in Table 8.6. 
Table 8.6 Components of the test samples used for testing the effect of 
gentamicin (G) on the effect of polymyxin B (PMB) on the viability of P. aeruginosa 
NCTC 6750 
Sample PMB* (ml) G* (ml) Phosphate buffer 
pH 6.0 to 
(ml) 
1. G 0.60 O/oW/V - 5.0 10 
2. G 0.30 %w/v - 2.5 10 
3. 0.15 %w/v - 1.25 10 
4. 0.072 %w/v - 0.6 10 
5. PMB 4000 U/ml 4 - 10 
6. PMB 4000 U/ml 4 5.0 10 
+ G 0.60 %w/v 
7. PMB 4000 U/ml 4 2.5 10 
+ G 0.30 %w/v 
8. PMB 4000 U/ml 4 1.25 10 
+ GO. 15 %w/v 
9. PMB 4000 U/ml 4 0.6 10 
+ G 0.072 %w/v 
PMB* = 0.0329 9 of polymyxin B sulphate ( 7690 U/mg ) in 25 ml of phosphate buffer pH 6.0 (10,000 
U/ml) 
G* = 0.4601 9 of gentamicin sulphate ( 652 J.lg/mg) in 25 ml of phosphate buffer pH 6.0 (1.2 %w/v) 
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8.3 Results and discussion 
8.3.1 Effect of thiomersal and trimethoprim 
The killing curves of all samples are shown in Fig. 8.1. Analysis of data was carried 
out using ANOV A ( p=0.05) at all contact times and log CFUs/ml. The killing 
curves of thiomersal 0.001 %w/v, trimethoprim 0.02 %w/v and thiomersal 0.001 
%\v/y plus trimethoprim 0.02 %w/v were not significantly different from the control 
( plots No.2. 7, 6 and 8). Thiomersal is known to be mainly a bacteriostatic agent 
and trimethoprim is a slowly bactericidal agent. P. aeruginosa is inherently 
resistant to trimethoprim due to the inability of the agent to penetrate the cell 
envelope and gain access to the dihydrofolate reductase enzyme [9,16]. As 
expected, thiomersal and trimethoprim alone at these concentrations were shown to 
be inactive against P. aeruginosa. The combinations of either thiomersal and 
trimethoprim or both together did not produce a significant effect on the activity of 
the polymyxin B 2000 U/ml. This is shown in plots No.1, 3, 4 and 5. 
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thiomersal (TMS), trimethoprim (TMP) and the combinations of these three substances. 
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8.3.2 Effect of neomycin 
8.3.2.1 Killing time determinations 
As mentioned in 8.2.2.2., neomycin alone at all concentrations did not show a 
marked effect on the viability of P. aeruginosa cells but the combination of 
neomycin with polymyxin B apparently slightly reduced the activity of polymyxin B 
against this organism. (Fig.8.2). Any such effect could contraindicate the use of 
neomycin with polymyxin B eye drops. Therefore chemical methods were used to 
investigate further if these two substances have a chemical interaction that may 
affect the availability of polymyxin B. 
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137 
8 ., ,..,,.., Ch . I' . . -'._.- emIca InteractIon between polymyxin B and neomycin 
The calibration curves of polymyxin B at the concentrations ranging from 10 to 250 
Vlml (200 nm) and 50 to 250 Vlml (220 nm) gave straight lines. These are shown in 
Figs. 8.3 and Fig 8.4. The absorbance readings of neomycin, polymyxin B and the 
combinations of these two substances at 200 nm and 220 nm were carried out and 
the results are shown in Tables 8.7 and 8.8. There was about a 15 % decrease in the 
absorbances of polymyxin B plus neomycin compared with polymyxin B alone at 
200 nm and about 1 to 5 % increase at 220 nm. The Student t-test of the 
absorbances of polymyxin B alone and polymyxin B plus neomycin at all 
concentrations both at 200 and 220 nm show that the decreaselincrease in the 
absorbance of these samples was not significant. The polymyxin B has maximum 
absorbance at 200 nm which is also the region were most of the other substances 
also absorb. This could be a problem when measuring the changes in the 
absorbance of polymyxin B at this wavelength. The experiment was repeated at 220 
nm but the increase in absorbance was not found to be significant. Therefore the 
absorbance was scanned at 200 to 300 nm. There were no changes in the spectrum 
of polymyxin B 2000 Vlml and polymyxin B 2000 Vlml plus either neomycin 0.08 
% or neomycin 0.16 % when they were superimposed. Thus, there was no strong 
evidence to suggest that chemical interaction between these two substances 
occurred. 
Neomycin is an aminoglycoside antibiotic which is active against many strains of 
Gram-negative bacteria but not against P. aeruginosa [1,9,76]. It can act as an 
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inhibitor of bacterial protein synthesis but also produce effects on the bacterial cell 
membrane. Neomycin, being cationic under physiological conditions, is accepted 
by anionic sites on the cell surface. In Gram-negative bacteria, anionic binding sites 
include the polar heads of phospholipids and lipopolysaccharide [1,16]. These are 
the same binding sites as for polymyxin B which also behaves as a cation [77]. 
Neomycin may compete with polymyxin B and therefore reduce polymyxin B 
activity on P. aeruginosa. This may be the explanation for the slight decrease in 
acitivity observed in Fig. 8.2. 
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Table 8.7 Absorbance readings of polymyxin B (PMB), neomycin (N) and the 
combination of these two substances at 200 nm 
Sample Absorbance at 200 nm % decrease t-test of 
Mean; n=3 ( SD) compared with absorbance 
PMB 200 U/ml compared with 
PMB 200 U/ml 
( p= 0.05) 
1. N 0.016 %w/v 0.0677 (0.0025) 
2. N 0.008 %w/v 0.0677 (0.0025) 
3. N 0.00384 %w/v 0.0667 (0.0029) 
4. N 0.00192 %w/v 0.0650 (0.0050) 
5. PMB 200 U/ml 0.5417 (0.0029) 
6. PMB 200 U/ml 0.4577 (0.0025) 15.5082 -
+ N 0.016 %w/v 
7. PMB 200 U/ml 0.4760 (0.0069) 12.1236 -
+ N 0.008 %w/v 
8. PMB 200 U/ml 0.4583 (0.0029) 15.3852 -
+ N 0.00384 %w/v 
9. PMB 200 U/ml 0.4683 (0.0029) 13.5391 -
+ N 0.00192 %w/v 
+ = significant difference 
no-significant difference 
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Table 8.8 Absorbance readings of polymyxin B (PMB), neomycin (N) and the 
combination of these two substances at 220 nm 
Sample Absorbance at 220 010 increase t-test of 
nm compared with absorbance 
Mean; n=3 ( SO) PMB 200 U/ml compared with 
PMB 2000 U/ml 
( p= 0.05) 
1. N 0.16 0/0 0.0550 (0.0021 ) 
2. N 0.08 0/0 0.0290 (0.0014) 
3. N 0.0384 0/0 0.0210 (0.0014) 
4. N 0.0192 % 0.0175 (0.0035) 
5. PMB 2000 U/ml 0.5325 (0.0035) 
6. PMB 2000 U/ml 0.5600 (0.0013) 5.1643 -
+ N 0.16 0/0 
7. PMB 2000 U/ml 0.5575 (0.0106) 4.6948 -
+ N 0.08 0/0 
8. PMB 2000 U/ml 0.5500 (0.0025) 3.2864 -
+ N 0.0384 010 
9. PMB 2000 U/ml 0.5425 (0.0035) 1.8779 -
+ N 0.0192 0/0 
+ = significant difference 
no-significant difference 
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8.3.3 Effect of gentamicin 
Fig. 8.5 and 8.6 show killing curves of gentamicin, polymyxin B and the 
combinations of both substances. The data was analysed by using ANOVA (p=0.05) 
of all contact times and log CFUs/ml. The results indicated that gentamicin at all 
concentrations except 0.018 and 0.009 %w/v showed more activity against P. 
aeruginosa than that of polymyxin B 2000 U/ml. The highest concentration of G 
(0.15 %w/\') reduced the number of bacteria from ~ 108 CFU/ml to less than 103 
\vithin 20 min. The other concentrations killed the test organism from ~ 108 
CFU'n11 to ~ 106 CFU/ml after contact time of 50 min. The combination of 
polymyxin B 2000 U/ml plus gentamicin 0.15, 0.075 or 0.036%w/v were more 
active against P. aeruginosa than polymyxin B 2000 U/ml plus gentamicin 0.018 or 
0.009 %w/v, gentamicin 0.018 and gentamicin 0.009 %w/v which were not 
significantly different from PMB 2000 U/ml alone. Gentamicin itself is more active 
than other aminoglycosides against P. aeruginosa and its activity against P. 
aeruginosa is ten-times more active than neomycin [1]. Unlike neomycin which did 
not show a significant effect against P. aeruginosa , gentamicin caused a greater 
effect on cell viability at concentrations of 0.15, 0.075, 0.036 %w/v than polymyxin 
B 2000 U/ml. Gentamicin 0.15 %w/v plus polymyxin B 2000 U/ml had a similar 
effect to gentamicin 0.15 %w/v alone. However, gentamicin at concentrations of 
0.075 and 0.036 %w/v combined with 2000 U/ml also added to the activity of the 
individual antibiotics against P. aeruginosa. Gentamicin, like neomycin, can bind 
to multiple sites on the cell surface which are also the binding sites for polymyxin B 
[77]. Gentamicin itself has antimicrobial activity. Even if it displaced some 
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polymyxin B the overall effect was either indifferent or additive. Neomycin has no 
little or no activity against P. aeruginosa and therefore the overall effect of 
combinations was inhibition. 
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8.4 Conclusion 
The effects of thiomersaL trimethoprim, neomycin and gentamicin singly and the 
combinations of these substances with polymyxin B on P. aeruginosa were 
investigated. Thioglycollate broth containing p-aminobenzoic acid (PABA) 0.16 
%\v/v and magnesium sulphate 1 %w/v was used as an inactivating recovery 
medium. Thiomersal 0.001 %w/v, trimethoprim 0.02 %w/v and thiomersal 0.001 
%w/v plus trimethoprim 0.02 %w/v when mixed in this medium did not show a 
significant effect on the viability of cell suspensions of P. aeruginosa. Neither did 
they enhance the effect of polymyxin B 2000 Vlml on the test organism. Neomycin 
at concentrations of 0.16, 0.08, 0.04 or 0.0192 %w/v slightly inhibited the activity 
of polymyxin B 2000 Vlml. The results with gentamicin were different from the 
results with the other antibacterials. Although neomycin and gentamicin have the 
same mode of action, only gentamicin is active against P. aeruginosa. Gentamicin 
at the concentrations of 0.15, 0.075 and 0.036 %w/v was more active than 
polymyxin B 2000 Vlml. Gentamicin 0.075 and 0.036 %w/v was also shown to 
add to the activity of polymyxin B 2000 Vlml on P. aeruginosa. It can be 
concluded from the above that the preservatives and the second antibacterials 
present in the tested eye drops did not have an effect on the activity of polymyxin B 
2000 Vlml with the exception of neomycin which had an inhibitory effect. In 
addition, thioglycollate broth containing p-aminobenzoic acid (PABA) 0.16 %w/v 
and magnesium sulphate 1 %w/v was suitable for use as an inactivating recovery 
medium for determining killing times for eye drops containing the tested 
concentrations of thiomersal, trimethoprim and neomycin. 
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Chapter 9 
Effect of heat on polymyxin B stability and activity 
9.1 Introduction 
This chapter \vas to determine the correlation between chemical stability and 
microbiological activity of polymyxin B standard material in aqueous solution and 
proprietary eye drops. As discussed in chapter 6 the microbiological assay was not 
considered suitable for determining the differences in microbiological activity of 
polymyxin B samples in the stability study. Therefore killing time determinations 
for polymyxin B in the presence of other antibacterials and preservatives contained 
in the formulations were developed as described in chapter 7 and 8. Although most 
of the ingredients in the proprietary eye drops did not affect polymyxin B activity 
against P. aeruginosa NCTC 6750, neomycin which was present in sample 2, 3,4, 5 
and 6 slightly reduced the effect of polymyxin B. The method developed for 
determining the killing times of the test samples were used also for samples 
containing neomycin. The inactivating recovery medium used was thioglycollate 
broth containing p-aminobenzoic acid (PABA) 0.16 %w/v and magnesium sulphate 
1 %w/v which was expected to inhibit any activity of thiomersal and trimethoprim 
against the test organism. The HPLC assay developed in chapter 2 was used in the 
investigations described in this chapter to determine the amount of polymyxin B left 
after heat treatment. 
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The major peak ( PB} ) was used to represent the amount of effective polymyxin B 
in the samples. Test samples were six eye drops ( sample 1-6 ) and polymyxin B in 
phosphate buffer pH 6.0 which were similar to those used in the stability study in 
chapter 3. They were stored at 43, 50, 55 and 60°C over a period of 500 h. Since 
all the samples stored at 60°C were used in the microbiological assay in chapter 6, 
the samples stored at 55°C were used for the killing time determinations described in 
this chapter. It was expected that the results would represent the microbiological 
activity of the undecomposed polymyxin B remaining in the eye drop formulations 
and the buffer. In addition, polymyxin B standard material was prepared in 
phosphate buffer pH 6.0 and heated at a series of higher temperatures ( 92-94 and 
115°C). Killing time determinations and HPLC assays for these samples were also 
carried out. 
9.2 Methods 
9.2.1 Killing time determinations 
P. aeruginosa NCTC 6750 was used as the test organism. Inoculum preparation for 
all experiments in this chapter were as described in 4.2.2.1 
The test solutions ( 150 J.lI ) were mixed with 150 J.lI of cell suspension in the first 
row of wells in the microtiter plates. The wells in rows 1 to 6 of the microtiter 
plates were primed with 200 J.lI of thioglycollate broth containing PABA 0.16 %w/v 
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and lnagnesium sulphate 1 %w/v. Phosphate buffer pH 6.0 was used as the control. 
Killing time determinations were carried out as described in 4.2.2.2. 
The term " activity" used in the following sections refers to microbiological activity 
of po IYlnyx in B against P. aeruginosa NCTC 6750. 
The preparations of the test samples were as follows: 
9.2.1.1 Polymyxin B in phosphate buffer pH 6.0 heated in a water bath ( 92-94 0g 
Standard solutions of polymyxin B 4000 Vlml were prepared by dissolving 0.0521 g 
of polymyxin B sulphate (7690 Vlmg) in 100 ml of phosphate buffer pH 6.0. Ten 
milliliters of this solution was filled into each of 6 screwcap bottles, respectively. 
The inner rubber lining of the metal caps were further lined with aluminum foil in 
order to prevent the adsorption and or absorption of the polymyxin B solution onto 
and into the rubber. 
The water bath was set at the highest temperature and the water was covered with 
polypropylene spheres in order to help maintain the temperature. The sample 
bottles and a bottle of 10 ml buffer were placed in the water bath when the 
temperature of water was at the required temperature and constant. A thermometer 
was placed in a bottle of buffer and the time was noted when the temperature had 
reached the required temperature and remained constant (92-94 °C). At time 
intervals of 30, 60, 90, 120 and 150 min, one bottle of sample was removed from the 
148 
\vater bath and cooled down to room temperature. The pH of each sample was 
determined before and after heating. 
9.2.1.2 Polymyxin B in phosphate buffer pH 6.0 heated in an autoclave ( 115 0g 
A standard solution of polymyxin B was prepared and filled into screwcap bottles as 
described in 9.2.1.1. 
The bench autoclave was switched on and the temperature allowed to rise to 100°C 
(~ 30 min). It was then switched off and the samples were placed in the chamber. 
The autoclaye \vas switched on again to allow the temperature and pressure to reach 
115°C and 10 Ib/inch2 ( about 5 min). The time was set for 30 min* after the above 
conditions had been achieved and the autoclave was switched off to cool down for 
30 min. Samples were then removed and cooled down to room temperature. This 
procedure was repeated for 60,90 and 120 min*. Each time a control bottle of 10 
ml phosphate buffer pH 6.0 was autoclaved with the test samples. The pH of each 
samples was measured before and after autoclaving. 
9.2.1.3 Polymyxin B in phosphate buffer pH 6.0 and polymyxin B eye drops heated 
at 55-oC 
Six samples of polymyxin B eye drops ( sample 1-6) and standard polymyxin B 
(16250 U/ml) prepared in phosphate buffer pH 6.0 were used as test samples. They 
were heated in the oven at 55°C over a period of 500 h. Chemical stability studies 
of these samples were carried out as described in chapter 3. They were kept in the 
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freezer (-20°C) and thawed 30 min before using for killing time determinations. 
Dilutions of test samples were made in phosphate buffer pH 6.0 to give a 
concentration of 4000 Vlml of polymyxin B. This was further diluted to 2000 Vlml 
in the first row of wells of the microtiter plates. The pH of test samples before and 
after heating \yere also measured. 
9.2.2 HPLC assay of heated polymyxin B 
Chemicals and reagents, apparatus and chromatographic conditions were as 
described in chapter 2. 
Freshly prepared standard polymyxin B was prepared by dissolving 0.0133 g of 
polymyxin B sulphate ( 7760 Vlmg ) in 25 ml phosphate buffer pH 6.0 to get the 
concentration of 4000 Vim!' All samples from 9.2.1 were kept in the freezer 
(-20°C) and thawed 30 min before injecting undiluted and in duplicate into the 
HPLC system. The percentage of polymyxin B remaining in the test samples was 
calculated by comparing the peak height of peak PB 1 of the test samples to the peak 
height of freshly prepared standard polymyxin B. 
The term 'percentage remaining' used In the following sections refers to the 
percentage remaining of peak PB 1 • 
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9.3 Results and discussion 
9.3.1 Polymyxin B sulutions in phosphate buffer pH 6.0 heated either in a 
\yaterbath ( 92-94 °c ) or autoclave (115°C) 
Fig. 9.1 and 9.3 show killing curves and chromatograms of polymyxin B heated at 
92-94 °c in a waterbath. The results indicate that heating polymyxin B at 92-94 °c 
reduced the activity of polymyxin B against P. aeruginosa as a function of time. 
Microbiological activity data is similar to chemical stability data which showed that 
the percentage remaining decreased as the heating time increased. ANOVA 
(p=0.05) of all contact times and log CFUs/ml indicated that only polymyxin B 
heated for a period of 150 min showed no significant effect on the test organism. 
The percentage of polymyxin B remaining as determined by the HPLC assay was 
less than 10 percent. Polymyxin B heated for shorter periods ( 30, 60, 90, and 120 
min) still possessed marked activity. The percentage remaining ranged from 43.60 
to 20.12 percent polymyxin. After heating for 120 min at 92-94 °c , about 20 
percent of the original polymyxin B reduced the number of P. aeruginosa from 1011 
CFU/ml to 107 CFU/ml within 60 min. It could be concluded that polymyxin B in 
phosphate buffer pH 6.0 retained sufficient microbiological activity if the percentage 
remaining was more than 20. This represent a concentration of 400 U/ml which in 
initial experiments showed comparable activity. 
Chromatograms of autoclaved polymyxin B in phosphate buffer pH 6.0 are shown in 
F· 94 Killing curves of all autoclaved samples were not significantly different Ig. . . 
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from the control ( ANOV A, p=0.05). This indicated that autoclaving at 115°C for 
30 min and longer destroyed all antibacterial activity. The amount of polymyxin B, 
as determined by HPLC, was also extensively decreased by the same heat treatment. 
Correlation between microbiological activity data and chemical stability data is 
consistent with the similarity of the results obtained at 92-94 °c. 
The pH of all polymyxin B samples heated in the waterbath and autoclave remained 
close to 6.0 after heat treatment as shown in Table 9.2. Therefore pH was not a 
factor in the polymyxin B activity and stability in this study. 
From the chromatograms in Figs. 9.3 and 9.4, the obvious peaks of decomposition 
products appeared near the solvent front. These new compounds did not seem to 
have activities against P. aeruginosa since the activity of polymyxin B after heat 
treatment appeared to depend on the amount of the remaining PB 1 
Table 9.1 Percentages remaining of the main component (PB1) of polymyxin B 
(4000 U/ml) prepared in phosphate buffer pH 6.0 and exposed to a series of elevated 
temperatures for fixed times. 
The results were obtained from the comparison of peak height of untreated polymyxin B at 
the same concentration as the test samples. 
Heat treatment sample Duration (min) % remaining of PB1 
Water bath (92-94°C) 30 43.60 
60 34.76 
90 24.70 
120 20.12 
150 <10 
Autoclave (115°C) 30 Extensively decomposed. 
60 All main peaks disappeared. 
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Fig. 9.1 Reduction in the CFU/ml with time for cell suspensions of P. aeruginosa NCTC 6750 produced by polymyxin B ( PMB ) 2000 U/ml 
untreated and heated in a waterbath at 92-94°C. 
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(a) (b) (c) (d) 
Fig. 9.3 Representative chromatograms of polymyxin B in phosphate buffer pH 
6.0 untreated (a) and heated at 92-94 °c for 30 min (b), 120 min (c) and 150 min 
(d). 
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(a) (b) (c) 
Fig. 9.4 Representative chromatograms of polymyxin B in phosphate buffer pH 6.0 
untreated (a) and heated at 115°C for 30 min (b) and 120 min (c). 
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Fig. 9.5 Representative chromatograms of samples untreated and heated at 55°C over a period of 331.5 h. 
(a) polymyxin 8 In phosphate buffer pH 6.0 untreated (b) polymyxin B in phosphate buffer pH 6.0 
(c) sample 1 (d) sample 2 (e) sample 3 (f) sample 4 (g) sample 5 (h) sample 6 . 
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Table 9.2 The pH of polymyxin B 4000 U/ml in phosphate buffer pH 6.0 after 
exposure to elevated temperatures for fixed times 
Temperature (oC) Duration (min) pH 
92-94°C 30 6.03 
60 6.03 
90 6.05 
120 6.05 
150 6.10 
115°C 30 6.05 
60 6.05 
90 6.08 
120 6.09 
Table 9.3 The pH of polymyxin B eye drops and polymyxin B 16,250 U/ml alone in 
phosphate buffer pH 6.0 before and after storage at 55°C over a period of 500 h 
Sample pH 
Before After 
1 5.67 6.18 
2 6.10 6.27 
3 6.92 7.24 
4 5.45 5.89 
5 5.41 5.85 
6 5.48 5.69 
PMB 6.00 6.25 
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9.3.2 The stability of polymyxin B in phosphate buffer pH 6.0 and polymyxin 
B eye drops stored at 55°C 
The activity of polymyxin B as determined by the reduction in CFU/ml produced by 
storing polymyxin B eye drops and polymyxin B in phosphate buffer pH 6.0 over a 
period of 500 h as compared with the activity of freshly prepared polymyxin B is 
shown in Fig. 9.2. The data was analyzed using ANOVA (p=0.05) of all the 
contact times and log CFU simI. 
From the killing curves in Fig. 9.2, four groups of samples can be classified. 
Sample 1 and sample 2 exhibited the most activity against P. aeruginosa. They 
showed a similar initial killing pattern to freshly prepared polymyxin B and also the 
heated polymyxin B but after 50 min contact they appaeared to be more active than 
the other solutions. Between 50 min and 60 min contact sample 1 and 2 had 
reduced the initial inoculum of almost 109 CFU/ml to less than 103 CFU/mI. Thus 
microbiological activity of sample 1 correlates well to the chemical stability data in 
chapter 3. However, sample 2 did not appeared to be as stable chemically but still 
exhibited high activity against the test organism. It is not clear why sample 2 was 
so active against the test organism unless some of the activity originated from 
degradation products. 
The second catagory of solutions included freshly prepared polymyxin B and heated 
polymyxin B. Both had an initial rapid killing effect at 10 min which was similar to 
sample 1. Unlike sample 1 however these two samples of polymyxin solutions did 
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not exhibit further marked activity after 10 min. Killing curves obtained using both 
samples were not significantly different (ANOV A, p=0.05). This is a perplexing 
result because it indicated that heating polymyxin B at 55°C for 500 h did not 
significantly affect the activity of polymyxin B in phosphate buffer at pH 6.0. The 
same heat treatment greatly reduced the concentration of polymyxin B as determined 
by HPLC (chapter 3). In fact simple polymyxin solution showed the highest degree 
of decomposition. For both polymyxin B prepared in phosphate buffer pH 6.0 
viithout any other ingredients and also for sample 2, the activities may result from 
the decomposition products which obviously appeared from 331.5 h as shown in 
Fig. 9.5. 
The third group included samples 4, 5 and 6 which exhibited medium level activity 
against P. aeruginosa over the period of 60 min. The microbiological data 
correlated to chemical stability data which showed that these three samples were 
very stable in the conditions used in the study. The decomposition rate constants 
were much lower than sample 2, 3 and polymyxin B alone. Sample 4, 5 and 6 were 
all produced by the same company and contained the same original concentration of 
polymyxin B. They were expected to have similar chemical stability and 
microbiological activity. 
Sample 3 was the least active sample. Similar results were obtained in the chemical 
stability investigation. This chemical data is presented in chapter 3. It was shown 
to have a high rate of decomposition. 
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It \vas assumed in this investigation that the concentration of polymyxin B in each 
sample was equal to the stated label concentration. On this basis the concentration 
of all the diluted samples used for killing time detenninations would be expected to 
be 2000 U/m!. 
compendia. 
Up to 30 percent overage of polymyxin is allowed by the various 
Thus it is highly likely that all the eye drops contain higher 
concentrations of polymyxin B than the concentration stated on the label. Although 
some polymyxin B decomposed during the stability study, the amount of effective 
polyn1yxin B was high enough to show similar activity to that of freshly prepared 
polymyxin B. It is difficult to compare polymyxin B activity among these samples 
if the original concentrations of polymyxin B in the test samples were higher than 
the stated label concentrations. Another factor is the different ratios of polymyxin 
B that could be present. The killing curves indicate the degree of lost activity once 
it has dropped lower than 100 percent of the labelled concentration. 
It can be seen from Fig. 9.2 that sample 3 showed the greatest loss of antibacterial 
activity. Samples 1, 2, 3, 4, 5 and 6 all retained marked activity after the same heat 
treatment. It is also obvious that pH plays an important role in polymyxin B 
stability and activity. The original pH of sample 3 was higher than the other 
samples (6.92). After heating the pH was even more alkaline (7.24). A high 
degree of decomposition of polymyxin B in sample 3 was shown in the data 
presented in chapter 3. This is consistent with earlier work [9,10,54,55] that 
polymyxin B in solution above pH 7 is not stable. In the case of sample 3 the pH 
could be expected to have an adverse effect on polymyxin B activity. 
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The sample of solution of polymyxin B in phosphate buffer pH 6.0 which had been 
heated at 55°C did not significantly lose activity compared with freshly prepared 
polymyxin B. The pH of polymyxin B solution changed only slightly after storage. 
Samples L 2. 4. 5, 6 also demonstrated marked activity after similar heat 
treatments. The pH before and after the stability study was close to 6.0. Perhaps it 
\yas not surprising that the chemical composition and microbiological activity of 
these samples remained high. The exceptions were the findings of the chemical 
assay for sample 2 and for the sample polymyxin B in phosphate buffer pH 6.0. 
Both indicated extensive chemical decomposition but both still possessed good 
antibacterial activity. Although the reason for this is not obvious from this study, 
the results emphasize the critical effect of pH on polymyxin B stability and 
microbiological activity in aqueous solution. There is still an unsolved question 
about the effect of decomposition products. 
9.3 Conclusion 
Microbiological activity data for polymyxin B in phosphate buffer pH 6.0 correlated 
to chemical stability data over the temperature range of 92-115 DC. Heating 
polymyxin B in phosphate buffer pH 6.0 at 92-94 °c in a waterbath and at 115°C in 
an autoclave from 30 to 150 min reduced the activity and the amount of the main 
component (PB l ) of polymyxin B as function of time. The microbiological 
activity of polymyxin B remained sufficient to reduce an inoculum of lOll CFU/ml 
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P. aerllginosa NCTC 6750 to 107 CFU/ml within 60 min even when the percentage 
of PB 1 reduced to about 20 percent of the labelled amount. 
It is difficult to correlate the microbiological activity data and chemical stability data 
for polyn1yxin B in phosphate buffer pH 6.0 with the polymyxin B eye drops ( 
sample 1-6 ) heated at 55°C over a period of 500 h. The difficulties are related to 
the lack of knowledge of the original concentration of polymyxin B in the samples 
and the microbiological activity of the decomposition products of polymyxin B. 
The results obtained at 55°C indicated the critical effect of pH on the 
microbiological activity and chemical stability of polymyxin B in aqueous solution. 
It is suggested that the decomposition products of polymyxin B which occurred at 
55°C in the solutions of pH 6.0 possessed microbiological activity. It is also 
suggested that at the same pH but higher temperatures ( 92-115 °C) the 
decomposition products were further degraded and did not show activity against the 
test organism. Further investigation on the microbiological activity of 
decomposition products of polymyxin B which occur at various pH and 
temperatures would seem to be needed in order to offer a possibility of clarifying 
this complex situation. 
163 
Chapter 10 Overall conclusions 
10.1 Correlation between chemical stability and microbiological 
activity 
The present work attempted to correlate chemical stability and microbiological 
actiyity of polymyxin B standard material and polymyxin B in proprietary eye drops . 
. .m HPLC method and a microbiological method were developed. It was postulated 
that the chemical data and microbiological data would correlate. However, only the 
results obtained at high temperatures (92-115 DC) were in agreement with this 
hypothesis. 
The results presented in this thesis indicate that the decomposition rate constants of 
polymyxin B in phosphate buffer pH 6.0 correlate over the temperature range from 
32 to 60°C. Differences in the chemical stability of the different proprietary eye 
drops were observed. The microbiological activity was determined by killing time 
determinations. The results obtained at 55°C showed that polymyxin B eye drops 
buffered at pH close to 6.0 retained a high proportion of the main component ( PB 1 ) 
and possessed marked microbiological activity after heating for 500 h. These 
results are consistent to previous findings [9,1 0,55,56]which concluded that pH 6.0 
was important for maintaing polymyxin B stability in aqueous solution. However, 
one eye drop sample and the polymyxin B standard material both prepared in buffer 
at a pH close to 6.0 exhibited marked microbiological activity although chemical 
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analysis indicated a high degree of decomposition. This may result from the 
antibacterial activity of the decomposition products of polymyxin B which were 
formed. 
The stability/activity results at higher temperatures (92-115 DC) demonstrated a 
correlation bet\yeen the chemical stability data and microbiological activity data. 
Heating polymyxin B in phosphate buffer pH 6.0 at these high temperatures reduced 
both the activity against P. aeruginosa NCTC 6750 and the percentage of the main 
component ( PB 1 ) as a function of time. The polymyxin retained observable 
antibacterial activity when the percentage PBI remaining was greater than 20%. It 
is suggested that further degradation took place at these temperatures and that these 
products did not possess antibacterial activity. 
The overall results suggest that the decomposition products of polymyxin B 
produced at 55°C or lower, in aqueous solution at pH 6.0 possess antibacterial 
activity and that pH is critical to the maintaining of the microbiological activity and 
stability of polymyxin B. The HPLC and microbiological methods used in the 
current study do not provide precise information which would confirm this. There 
are a number of limitations. Polymyxin B itself is a complex substance containing 
at least 13 components. Each component could decompose to various 
decomposition products depending on many factors such as pH and temperature. 
The current HPLC assay cannot determine the amount of the individual components 
and their decomposition products. It is difficult to explain the chemical stability 
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results of polymyxin B without more information on the decomposition kinetics of 
the individual components of polymyxin B. 
It is also important to investigate whether or not the decomposition products exhibit 
microbiological activity. The microbiological assay by the agar plate diffusion was 
not suitable for monitoring the potency of polymyxin B in the stability study. 
Therefore. killing time determinations for polymyxin B standard material and 
polyn1yxin B eye drops were developed. The advantage of this method is that the 
actiyity of each undecomposed and decomposed sample could be easily 
distinguished from the killing curves. However, the killing curve represents the 
actiyity of total polymyxin B but the activity of the individual components cannot be 
sho\\ n by this method. PB2 has been shown in other studies to be more active than 
PB 1 against B. bronchiseptica when determined by the agar plate diffusion assay 
[15.42]. However, there is no information about the activity of the individual 
components of polymyxin B against P. aeruginosa. Because of the heterogeneous 
component of polymyxin B, the ratio of each component in each sample could well 
be different. When the decomposition process occurs, the amount of active 
polymyxin B and its decomposition products in each test sample is likely to be in 
different proportions. In addition, the lack of knowledge of the activity of the 
decomposition products of polymyxin B makes the comparison between the activity 
of decomposed samples difficult. It cannot be finally concluded from this study that 
the decomposition products of polymyxin B possess antibacterial activity. A 
difficulty was also encountered with a lack of absolute consistency with the response 
of polymyxin B activity obtained between experiments. 
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The variation of polymyxin B activity as shown in chapter 9 and also chapter 7 and 8 
lllay result from many factors. Possible explanations involve Mg2+ and phosphate 
Ions. Mg2+ has been reported as a major cation in P. aeruginosa walls [78]. 
\\'ithin the outer membrane , the Mg2+ ions associate electrostatically with the 
phosphate residues attached to the lipid A and core oligosaccharide regions of the 
lipopolysaccharide (LPS) molecules [79]. Polymyxin B, as a polycationic 
compound. is able to disrupt the outer membrane permeability barrier by displacing 
the ~lg2+ binding sites on LPS. The positively charged groups of polymyxin interact 
\\ith the negatively charged phosphates [77]. It has been suggested that phosphate 
availability itself may influence polymyxin susceptibility in P. aeruginosa, perhaps 
by modulating LPS phosphorylation, but results on this aspect are contradictory 
[75]. In the present study phosphate buffer was used as a solvent for polymyxin B. 
The extra amount of phosphate in the system tended to reduce the activity of 
polymyxin B on the test organism as shown in chapter 7. This is consistent with the 
comment by Edwards [80] that soap, phosphatides and phosphate ions all antagonise 
the drug's activity. Polymyxin B could bind to phosphate groups available both in 
the solution and at the binding sites on LPS. In addition Mg2+ was added in the 
medium as an inactivator in the killing time determination of polymyxin B. Like 
phosphate ions, the Mg2+ is known to inhibit polymyxin B activity [14,66-68]. It is 
likely that both ions inhibit the polymyxin's activity by competing for the same 
binding sites. The effective amount of polymyxin B would therefore depend on the 
available binding sites on LPS. This may have varied between experiments. The 
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reason for this variation is not clear at present. This may lead to the observed 
inconsistency in the determination of polymyxin B activity. 
10.2 Further work 
In order to extend the understanding of the chemical stability and microbiological 
activity of polyn1yxin B, further work should include: 
• investigations of the degradation mechanisms of polymyxin B which occur at 
various pHs and temperatures, 
• development of quantitative methods of analysing the decomposition products of 
polymyxin B by more highly resolving techniques, 
• investigations of the microbiological activity of the decomposition products of 
polymyxin B which occur at various pHs and temperatures. 
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